

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

ABIRATERONE

Products Affected

- *abiraterone acetate*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Castration-resistant metastatic prostate cancer and used in combination with prednisone, or B.) High risk, castration-sensitive metastatic prostate cancer and used in combination with prednisone
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or urologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

ACITRETIN

Products Affected

- *acitretin*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Severely impaired liver or kidney function, B.) Chronic abnormally elevated blood lipid values, C.) Concomitant use of methotrexate or tetracyclines, D.) Pregnancy
Required Medical Information	Diagnosis of severe, recalcitrant psoriasis (including plaque, guttate, erythrodermic palmar- plantar and pustular) AND patient must have tried and failed, contraindication or intolerance to one formulary first line agent (e.g., Topical Corticosteroids (betamethasone, fluocinonide, desoximetasone), Topical Calcipotriene/Calcitriol, Topical Calcipotriene, OR Topical Tazarotene)
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a dermatologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

ACTIMMUNE

Products Affected

- ACTIMMUNE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Chronic granulomatous disease for use in reducing the frequency and severity of serious infections, or B.) Severe, malignant osteopetrosis (SMO)
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

ADEMPAS

Products Affected

- ADEMPAS

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Concomitant administration with nitrates or nitric oxide donors (such as amyl nitrate) in any form, B.) Concomitant administration with phosphodiesterase inhibitors, including specific PDE-5 inhibitors (such as sildenafil, tadalafil, or vardenafil) or non-specific PDE inhibitors (such as dipyridamole or theophylline), C.) Pregnancy, or D.) Patients with pulmonary hypertension associated with idiopathic interstitial pneumonia
Required Medical Information	Diagnosis of one of the following A.) Pulmonary arterial hypertension (WHO group I) and diagnosis was confirmed by right heart catheterization or Doppler echocardiogram if patient is unable to undergo a right heart catheterization (e.g., patient is frail, elderly, etc.), or B.) Chronic thromboembolic pulmonary hypertension (CTEPH, WHO group 4) and patient has persistent or recurrent disease after surgical treatment (e.g., pulmonary endarterectomy) or has CTEPH that is inoperable (Female patients must be enrolled in the ADEMPAS REMS program)
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or cardiologist
Coverage Duration	Initial: 6 months, Renewal: 12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

AFINITOR DISPERZ

Products Affected

- AFINITOR DISPERZ

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Tuberous sclerosis complex (TSC)-associated partial-onset seizures, or B.) Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in patients who are not candidates for curative surgical resection
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or neurologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

**H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021**

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

ALECENSA

Products Affected

- ALECENSA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of metastatic anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer as detected by an FDA-approved test
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

ALKINDI

Products Affected

- ALKINDI SPRINKLE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet all of the following 1.) Diagnosis of adrenocortical insufficiency and 2.) Patient requires dosages not available with other available formulations of hydrocortisone
Age Restrictions	18 years of age and younger
Prescriber Restrictions	Prescribed by or in conjunction with an endocrinologist or pediatrician
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

ALOSETRON

Products Affected

- *alosetron hcl*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Constipation, B.) History of Chronic or severe constipation or sequelae from constipation, C.) History of ischemic colitis, intestinal obstruction, stricture, toxic megacolon, GI perforation, adhesions, diverticulitis, Crohns disease, ulcerative colitis, D.) History of severe hepatic impairment, E.) History of impaired intestinal circulation, thrombophlebitis, or hypercoagulable state, or F.) Coadministration with fluvoxamine
Required Medical Information	Diagnosis of irritable bowel syndrome, severe diarrhea-predominant
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

ALPHA-1 PROTEINASE INHIBITOR

Products Affected

- PROLASTIN-C INTRAVENOUS SOLUTION RECONSTITUTED

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of alpha-1 proteinase inhibitor (alpha-1 antitrypsin) deficiency in adult patients with emphysema
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist
Coverage Duration	12 months
Other Criteria	B vs D determination required per CMS guidance
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

ALUNBRIG

Products Affected

- ALUNBRIG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of anaplastic lymphoma kinase-positive (ALK) metastatic non-small cell lung cancer (NSCLC)
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

AMBRISENTAN

Products Affected

- *ambrisentan*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Pregnancy, or B.) Idiopathic pulmonary fibrosis (IPF), including those with pulmonary hypertension
Required Medical Information	Diagnosis of pulmonary arterial hypertension classified as WHO Group I, confirmed by right heart catheterization or Doppler echocardiogram if patient is unable to undergo a right heart catheterization (e.g., patient is frail, elderly, etc.)
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or cardiologist
Coverage Duration	Initial: 6 months, Renewal: 12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

APOKYN

Products Affected

- APOKYN SUBCUTANEOUS SOLUTION CARTRIDGE

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with 5-HT(3) receptor antagonists (e.g. ondansetron, granisetron, dolasetron, palonosetron, alosetron etc.)
Required Medical Information	Diagnosis of Parkinson's disease (PD) and patient is experiencing acute intermittent hypomobility (defined as off episodes characterized by muscle stiffness, slow movements, or difficulty starting movements)
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

ARCALYST

Products Affected

- ARCALYST

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells Syndrome (MWS), or B.) Deficiency of interleukin-1 receptor antagonist (DIRA) and patient requires maintenance therapy for remission
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

ARIKAYCE

Products Affected

- ARIKAYCE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of pulmonary Mycobacterium avium complex (MAC) infection and used as part of a combination antibacterial regimen in treatment refractory patients
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an infectious disease specialist or pulmonologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

**H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021**

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

AURYXIA

Products Affected

- AURYXIA

PA Criteria	Criteria Details
Exclusion Criteria	Iron overload syndrome (e.g. hemochromatosis)
Required Medical Information	Diagnosis of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a hematologist or nephrologist
Coverage Duration	12 months
Other Criteria	Ferric Citrate is NOT approvable for iron deficiency anemia per Part D law
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

AUSTEDO

Products Affected

- AUSTEDO

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Suicidal ideation and/or untreated or inadequately treated depression, B.) Hepatic impairment, C.) Taking MAOIs, reserpine, or tetrabenazine
Required Medical Information	Diagnosis of one of the following A.) Chorea associated with Huntington's disease (Huntington's chorea), or B.) Tardive dyskinesia
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or psychiatrist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

AYVAKIT

Products Affected

- AYVAKIT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of unresectable or metastatic gastrointestinal stromal tumor, with a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

BALVERSA

Products Affected

- BALVERSA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations and patient has progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or urologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

BENLYSTA

Products Affected

- BENLYSTA SUBCUTANEOUS

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Active, autoantibody-positive, system lupus erythematosus (SLE), or B.) Active lupus nephritis and patient is receiving standard therapy
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a nephrologist or rheumatologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

**H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021**

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

BEXAROTENE

Products Affected

- *bexarotene*

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy
Required Medical Information	Diagnosis of cutaneous T-cell lymphoma (CTCL) and patient is not a candidate for or had an inadequate response, is intolerant to, or has a contraindication to at least one prior systemic therapy (e.g., corticosteroids) for cutaneous manifestations of CTCL
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

**H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021**

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

BOSENTAN

Products Affected

- *bosentan*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Concomitant cyclosporine A or glyburide therapy, or B.) Pregnancy
Required Medical Information	Diagnosis of pulmonary arterial hypertension (WHO Group I) and patient has New York Heart Association (NYHA) Functional Class II-IV, confirmed by right heart catheterization or Doppler echocardiogram if patient is unable to undergo a right heart catheterization (e. g., patient is frail, elderly, etc.)
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with pulmonologist or cardiologist
Coverage Duration	Initial: 6 months, Renewal: 12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

BOSULIF

Products Affected

- BOSULIF

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or inadequate response to prior therapy, or B.) Newly diagnosed chronic phase Philadelphia chromosome-positive (Ph+) CML
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

BRAFTOVI

Products Affected

- BRAFTOVI ORAL CAPSULE 75 MG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) unresectable or metastatic melanoma with documented BRAF V600E or V600K mutation as detected by a FDA-approved test and used in combination with binimetinib, or B.) metastatic colorectal cancer with documented BRAF V600E mutation as detected by an FDA-approved test and patient has received prior therapy. Must be used in combination with cetuximab.
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

BRUKINSA

Products Affected

- BRUKINSA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of A.) Mantle Cell Lymphoma (MCL) and patient has received at least one prior therapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

CABOMETYX

Products Affected

- CABOMETYX

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Advanced renal cell carcinoma, B.) Advanced hepatocellular carcinoma (HCC) and patient has been previously treated with sorafenib, or C.) Advanced renal cell carcinoma and used as first line treatment in combination with nivolumab
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

CALQUENCE

Products Affected

- CALQUENCE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Mantle cell lymphoma (MCL) and patient has received at least 1 prior therapy, B.) Chronic lymphocytic leukemia (CLL), or C.) Small lymphocytic lymphoma (SLL)
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

CAPRELSA

Products Affected

- CAPRELSA

PA Criteria	Criteria Details
Exclusion Criteria	Congenital long QT syndrome
Required Medical Information	Diagnosis of metastatic or unresectable locally advanced medullary thyroid cancer (MTC) AND disease is symptomatic or progressive
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

CARBAGLU

Products Affected

- CARBAGLU

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) N-acetyl glutamate synthase (NAGS) deficiency with acute or chronic hyperammonemia, or B.) Propionic or methylmalonic acidemia with acute hyperammonemia
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

CAYSTON

Products Affected

- CAYSTON

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of cystic fibrosis (confirmed by appropriate diagnostic or genetic testing) and patient has suspected or confirmed <i>Pseudomonas aeruginosa</i> infection
Age Restrictions	7 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

CINRYZE

Products Affected

- CINRYZE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) hereditary angioedema, used in prevention of angioedema attacks, or B.) hereditary angioedema, used in prevention of acute abdominal, facial, or laryngeal attacks
Age Restrictions	6 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a hematologist, immunologist, or allergist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

CLOBAZAM

Products Affected

- *clobazam*
- SYMPAZAN

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of seizures associated with Lennox-Gastaut syndrome
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

CNS STIMULANTS

Products Affected

- armodafinil*
- modafinil*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Obstructive sleep apnea (OSA) confirmed by sleep lab evaluation, B.) Narcolepsy confirmed by sleep lab evaluation, or C.) Shift work disorder (SWD)
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

COMETRIQ

Products Affected

- COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG
- COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG
- COMETRIQ (60 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of progressive, metastatic medullary thyroid cancer
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

COPIKTRA

Products Affected

- COPIKTRA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A) chronic lymphocytic leukemia, OR B) small lymphocytic lymphoma, OR C) follicular lymphoma, AND disease is relapsed or refractory, AND patient has history of at least 2 prior therapies
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

**H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021**

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

CORLANOR

Products Affected

- CORLANOR ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Decompensated acute heart failure, B.) hypotension (i.e. blood pressure less than 90/50 mmHg), C.) sick sinus syndrome or sinoatrial block or 3rd degree AV block (unless a functioning demand pacemaker is present), D.) bradycardia (i.e., resting heart rate less than 60 bpm prior to treatment), or E.) Severe hepatic impairment (Child-Pugh C)
Required Medical Information	Diagnosis of one of the following A.) stable, symptomatic chronic heart failure with left ventricular ejection fraction 35% or less, who are in sinus rhythm with resting heart rate 70 beats per minute or more and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use, or B.) stable, symptomatic heart failure due to dilated cardiomyopathy in patients who are in sinus rhythm with an elevated heart rate
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

COSENTYX

Products Affected

- COSENTYX (300 MG DOSE)
- COSENTYX SENSOREADY (300 MG)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Ankylosing spondylitis and patient has trial and failure, contraindication, or intolerance to two preferred products, (i.e. Humira, Enbrel), B.) Moderate to severe plaque psoriasis and patient has trial and failure, contraindication, or intolerance to two preferred products, (i.e. Humira, Enbrel, Skyrizi, Stelara), C.) Active psoriatic arthritis and patient has trial and failure, contraindication, or intolerance to two preferred products, (i.e. Humira, Enbrel, Stelara, Xeljanz), or D.) Non-radiographic axial spondyloarthritis
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	Screening for latent tuberculosis infection is required prior to initiation of treatment
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

COTELLIC

Products Affected

- COTELLIC

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of unresectable or metastatic malignant melanoma with BRAF V600E OR V600K mutation, and documentation of combination therapy with vemurafenib (Zelboraf)
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

CYSTADROPS

Products Affected

- CYSTADROPS

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Demonstrated cysteamine hypersensitivity, B.) Demonstrated penicillamine hypersensitivity
Required Medical Information	Diagnosis of cystinosis and patient has corneal cystine crystal accumulation
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

CYSTARAN

Products Affected

- CYSTARAN

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Demonstrated cysteamine hypersensitivity, B.) Demonstrated penicillamine hypersensitivity
Required Medical Information	Diagnosis of cystinosis and patient has corneal cystine crystal accumulation
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

DALFAMPRIDINE

Products Affected

- *dalfampridine er*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) History of seizure. B.) Moderate or severe renal impairment (creatinine clearance less than or equal to 50 mL/minute)
Required Medical Information	Diagnosis of multiple sclerosis and patient must demonstrate sustained walking impairment, but with the ability to walk 25 feet (with or without assistance) prior to starting dalfampridine
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

DAURISMO

Products Affected

- DAURISMO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of newly diagnosed acute myeloid leukemia (AML) and used in combination with cytarabine in patients 75 years of age or older OR in patients that have comorbidities that preclude use of intensive induction chemotherapy
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

DEFERASIROX

Products Affected

- *deferasirox granules*
- *deferasirox oral tablet*
- *deferasirox oral tablet soluble*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Creatinine clearance less than 40 mL/min, B.) Poor performance status, C.) Platelet count less than 50 x 10 ⁹ /L, D.) Advanced malignancy, E.) High-risk myelodysplastic syndrome (MDS)
Required Medical Information	Diagnosis of one of the following A.) Chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes who have liver iron concentrations of at least 5 mg Fe/g dry weight AND serum ferritin level greater than 300 mcg/L, or B.) Chronic iron overload due to blood transfusions (transfusion hemosiderosis) as evidenced by transfusion of at least 100 mL/kg packed red blood cells AND serum ferritin level greater than 1000 mcg/L
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

DEFERIPRONE

Products Affected

- *deferiprone*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet all of the following 1.) Diagnosis of transfusional iron overload due to thalassemia syndromes, 2.) Patient has failed prior chelation therapy, and 3.) Patient has an absolute neutrophil count greater than $1.5 \times 10^9/L$
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

DIACOMIT

Products Affected

- DIACOMIT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of severe myoclonic epilepsy in infancy (Dravet syndrome) in patients taking clobazam
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

DICLOFENAC TOPICAL

Products Affected

- *diclofenac sodium external gel 3 %*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of Actinic keratosis
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

DIMETHYL FUMARATE

Products Affected

- *dimethyl fumarate oral*
- *dimethyl fumarate starter pack*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Relapsing forms of multiple sclerosis (e.g., clinically isolated syndrome, relapsing-remitting MS, active secondary progressive disease, or progressive-relapsing MS), or B.) Patient has experienced a first clinical episode and has MRI features consistent with multiple sclerosis
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

DOJOLVI

Products Affected

- DOJOLVI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of Long-chain fatty acid oxidation disorder (LC-FAOD)
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

DRONABINOL

Products Affected

- *dronabinol*

PA Criteria	Criteria Details
Exclusion Criteria	Sesame oil hypersensitivity
Required Medical Information	Diagnosis of one of the following A.) Anorexia associated to AIDS, or B.) Chemotherapy-induced nausea and vomiting
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	6 months
Other Criteria	B vs D determination required per CMS guidance
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

DUPIXENT

Products Affected

- DUPIXENT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Moderate to severe atopic dermatitis and patient has trial and failure, contraindication, or intolerance to two medium to high potency topical corticosteroids (e.g., mometasone, triamcinolone, fluocinolone, betamethasone, etc.), or B.) Eosinophilic phenotype or oral corticosteroid- dependent moderate to severe asthma and used as an adjunct treatment, or C.) Chronic rhinosinusitis with nasal polyposis and used as an adjunct treatment
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an allergist, dermatologist, immunologist, otolaryngologist, pulmonologist, or rheumatologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

EMGALITY

Products Affected

- EMGALITY
- EMGALITY (300 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Chronic or episodic migraine disorder and patient has documented trial, inadequate response, or contraindication to at least 1 generic beta-blocker agent or generic anti-epileptic agent used in migraine prevention (i.e., propranolol, topiramate, valproic acid, divalproex), or B.) Episodic cluster headache
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

EMSAM

Products Affected

- EMSAM

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Concomitant use with any of the following: SSRIs, SNRIs, clomipramine, imipramine, meperidine, tramadol, methadone, pentazocine, propoxyphene, dextromethorphan, carbamazepine, or B.) Pheochromocytoma
Required Medical Information	Diagnosis of major depressive disorder and patient had trial of at least 2 generic oral antidepressants from differing classes (at least one should be from the following list: selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, mirtazapine, or bupropion unless contraindicated), unless unable to take any oral medication AND Patient had an adequate washout period (for patients previously on agents requiring a washout period)
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

ENBREL

Products Affected

- ENBREL MINI
- ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML
- ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- ENBREL SUBCUTANEOUS SOLUTION RECONSTITUTED
- ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Moderate to severe rheumatoid arthritis, B.) Moderate to severe polyarticular juvenile idiopathic arthritis, C.) Psoriatic arthritis, D.) Ankylosing spondylitis, or E.) Moderate to severe chronic plaque psoriasis in patients who are candidates for systemic therapy or phototherapy
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	Screening for latent tuberculosis infection is required prior to initiation of treatment
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

ENDARI

Products Affected

- ENDARI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Acute sickle cell disease, or B.) Short bowel syndrome and combined with recombinant human growth hormone
Age Restrictions	5 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

**H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021**

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

ENSPRYNG

Products Affected

- ENSPRYNG

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Active Hepatitis B infection, or B.) Active or untreated latent tuberculosis
Required Medical Information	Diagnosis of neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody positive
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist, immunologist, or ophthalmologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

ENTRESTO

Products Affected

- ENTRESTO

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) History of angioedema related to previous ACE inhibitor or ARB therapy, B.) Concomitant use or use within 36 hours of ACE inhibitors, or C.) Concomitant use of aliskiren in patients with diabetes
Required Medical Information	Diagnosis of one of the following A.) Chronic heart failure, NYHA Class II to IV, or B.) Symptomatic heart failure with systemic left ventricular systolic dysfunction
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

EPIDIOLEX

Products Affected

- EPIDIOLEX

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Lennox-Gastaut syndrome, or B.) Severe myoclonic epilepsy in infancy (Dravet syndrome), or C.) Seizures associated with tuberous sclerosis complex
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

EPOETIN THERAPY

Products Affected

- RETACRIT INJECTION SOLUTION UNIT/ML, 4000 UNIT/ML, 40000
10000 UNIT/ML, 10000 UNIT/ML(1ML), UNIT/ML
2000 UNIT/ML, 20000 UNIT/ML, 3000

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Supporting statement of diagnosis from physician
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	B vs D determination required per CMS guidance
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

ERIVEDGE

Products Affected

- ERIVEDGE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Metastatic basal cell carcinoma, or B.) Locally advanced basal cell carcinoma that has recurred following surgery or the patient is not a candidate for surgery or radiation
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

ERLEADA

Products Affected

- ERLEADA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Nonmetastatic, castration-resistant prostate cancer, or B.) Metastatic, castration-sensitive prostate cancer
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or urologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

ERLOTINIB

Products Affected

- *erlotinib hcl*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Locally advanced, unresectable, or metastatic pancreatic cancer and erlotinib will be used in combination with gemcitabine, or B.) Locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility AND one of the following 1.) erlotinib will be used as first-line treatment, OR 2.) failure with at least one prior chemotherapy regimen, OR 3.) no evidence of disease progression after four cycles of first-line platinum-based chemotherapy and erlotinib will be used as maintenance treatment
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

ESBRIET

Products Affected

- ESBRIET

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of idiopathic pulmonary fibrosis
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

EVEROLIMUS

Products Affected

- AFINITOR ORAL TABLET 10 MG
- *everolimus oral tablet 2.5 mg, 5 mg, 7.5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery, B.) Advanced hormone receptor-positive, HER2 negative breast cancer in postmenopausal women and taken in combination with exemestane, after failure with letrozole or anastrozole, C.) Progressive, well-differentiated, nonfunctional neuroendocrine tumors of gastrointestinal or lung origin and disease is unresectable, locally advanced, or metastatic, D.) Pancreatic progressive neuroendocrine tumors and disease is unresectable, locally advanced, or metastatic, E.) Advanced renal cell carcinoma (RCC) after failure with sunitinib or sorafenib, F.) Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in patients who are not candidates for curative surgical resection
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or neurologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

EVRYSDI

Products Affected

- EVRYSDI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of spinal muscular atrophy (SMA)
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

FARYDAK

Products Affected

- FARYDAK

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet all of the following 1.) Diagnosis of multiple myeloma, 2.) Medication is being used in combination with Velcade (bortezomib) and dexamethasone, 3.) Patient has received at least two prior treatment regimens, including Velcade (bortezomib) and an immunomodulatory agent [e.g., Revlimid (lenalidomide), Thalomid (thalidomide)]
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

FEBUXOSTAT

Products Affected

- *febuxostat*

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use of azathioprine or mercaptopurine
Required Medical Information	Diagnosis of Gout and all of the following 1.) documented inadequate treatment response, adverse event, or contraindication to maximally titrated dose of Allopurinol, and 2.) patients with established cardiovascular disease, prescriber attests that benefit of treatment outweighs the risk of treatment
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

FENTANYL ORAL

Products Affected

- *fentanyl citrate buccal lozenge on a handle*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Management of acute or postoperative pain (including headache/migraine, dental pain, and use in the emergency room), B.) Use in opioid non-tolerant patients
Required Medical Information	Must meet all of the following 1.) Diagnosis of cancer-related breakthrough pain, 2.) Patient is currently receiving/tolerant to around-the-clock opioid therapy for persistent cancer pain, and 3.) Patient and prescriber are enrolled in the TIRF REMS Access Program
Age Restrictions	16 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

FENTANYL PATCH

Products Affected

- *fentanyl*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Management of acute or postoperative pain (including headache/migraine, dental pain, and use in the emergency room), B.) Use in opioid non-tolerant patients
Required Medical Information	Must meet all of the following 1.) Patient is opioid tolerant (taking for one week or longer at least 60mg of morphine or equivalent daily), and 2.) Patient has tried at least one extended release oral opioids or is unable to take extended release oral opioids secondary to allergy, adverse events, swallowing difficulty, or uncontrollable nausea/vomiting
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

FERRIPROX

Products Affected

- FERRIPROX ORAL SOLUTION
- FERRIPROX ORAL TABLET 1000 MG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet all of the following 1.) Diagnosis of transfusional iron overload due to thalassemia syndromes, 2.) Patient has failed prior chelation therapy, and 3.) Patient has an absolute neutrophil count greater than $1.5 \times 10^9/L$
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

FINTEPLA

Products Affected

- FINTEPLA

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Concomitant use of an MAOI, or B.) Use within 14 days of discontinuing an MAOI
Required Medical Information	Diagnosis of Severe myoclonic epilepsy in infancy (Dravet syndrome)
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

FIRAZYR

Products Affected

- FIRAZYR

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of hereditary angioedema AND medication will be used for the treatment of acute attacks.
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a hematologist, immunologist, or allergist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

**H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021**

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

FIRMAGON

Products Affected

- FIRMAGON (240 MG DOSE)
- FIRMAGON SUBCUTANEOUS SOLUTION RECONSTITUTED 80 MG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of advanced or metastatic prostate cancer
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

FORTEO

Products Affected

- FORTEO SUBCUTANEOUS SOLUTION PEN-INJECTOR
- *teriparatide (recombinant)*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Patient has previous trial and failure, contraindication, or intolerance to a bisphosphonate AND diagnosis of one of the following A.) osteoporosis in postmenopausal female patient with high risk for fracture and patient has history of or contraindication to Tymlos, B.) primary or hypogonadal osteoporosis in male patient with high risk for fracture, or C.) osteoporosis due to associated sustained systemic glucocorticoid therapy in patient with high risk for fracture
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Initial: 12 months, Renewal: 12 months (Maximum 24 month treatment per patient lifetime)
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

FYCOMPA

Products Affected

- FYCOMPA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Partial-onset seizures with or without secondary generalization, or B.) Primary generalized tonic-clonic seizure disorder
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

GATTEX

Products Affected

- GATTEX

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of short bowel syndrome and patient is dependent on parenteral support
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

GAVRETO

Products Affected

- GAVRETO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test, B.) Advanced or metastatic RET-mutant medullary thyroid cancer and patient requires systemic therapy, or C.) Advanced or metastatic RET fusion-positive thyroid and patient requires systemic therapy and is radioactive iodine-refractory, when radioactive iodine is appropriate
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

GILENYA

Products Affected

- GILENYA ORAL CAPSULE 0.5 MG

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Recent (within the last 6 months) occurrence of: myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III/IV heart failure, B.) History or presence of Mobitz Type II 2nd degree or 3rd degree AV block or sick sinus syndrome, unless patient has a pacemaker, C.) Baseline QTC interval greater than or equal to 500 milliseconds, D.) Receiving concurrent treatment with Class Ia or Class III anti-arrhythmic drugs (quinidine, procainamide, amiodarone, sotalol)
Required Medical Information	Diagnosis of one of the following A.) Relapsing forms of multiple sclerosis (e.g., clinically isolated syndrome, relapsing-remitting MS, active secondary progressive disease, or progressive-relapsing MS), or B.) Patient has experienced a first clinical episode and has MRI features consistent with multiple sclerosis
Age Restrictions	10 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

GILOTRIF

Products Affected

- GILOTRIF

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Metastatic non-small cell lung cancer (NSCLC) in patients whose tumors have nonresistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test, or B.) Metastatic squamous NSCLC with progression after platinum-based chemotherapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

GLATIRAMER

Products Affected

- COPAXONE SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- *glatiramer acetate*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Relapsing forms of multiple sclerosis (e.g., clinically isolated syndrome, relapsing-remitting MS, active secondary progressive disease, or progressive-relapsing MS), or B.) Patient has experienced a first clinical episode and has MRI features consistent with multiple sclerosis
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

GOCOVRI

Products Affected

- GOCOVRI

PA Criteria	Criteria Details
Exclusion Criteria	Patients with end-stage renal disease (ESRD, CrCl below 15 ml/min/m ²)
Required Medical Information	Diagnosis of one of the following A.) Parkinson disease and patient is experiencing dyskinesia, receiving levodopa based therapy, and has documented trial and failure to amantadine immediate release, B.) Extrapyrasidal disease and has documented trial and failure to amantadine immediate release, or C.) Parkinson disease and patient is experiencing "off" episodes, receiving levodopa/carbidopa based therapy, and has documented trial and failure to amantadine immediate release
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

GROWTH HORMONE

Products Affected

- OMNITROPE SUBCUTANEOUS SOLUTION CARTRIDGE
- OMNITROPE SUBCUTANEOUS SOLUTION RECONSTITUTED

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Use for growth promotion in pediatric patients with closed epiphyses, B.) Acute critical illness caused by complications following open-heart or abdominal surgery, multiple accidental trauma, or acute respiratory failure, C.) Active malignancy, D.) Active proliferative or severe nonproliferative diabetic retinopathy, E.) Prader-Willi Syndrome in patients who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment
Required Medical Information	Diagnosis of pediatric indication: A.) GHD and bone age at least 1 year or 2 standard deviations (SD) delayed compared with chronological age and 2 stim tests with peak GH secretion below 10 ng/mL or IGF-1/IGFBP3 level more than 2 SDS below mean if CNS pathology, h/o irradiation, or proven genetic cause, B.) SGA and birth weight or length 2 or more SDS below mean for gestational age and fails to manifest catch up growth by age 2 (height 2 or more SDS below mean for age and gender), C.) CRI and nutritional status has been optimized, metabolic abnormalities have been corrected, and patient has not had renal transplant D.) SHOX deficiency or Noonan syndrome E.) PWS confirmed by genetic testing, F.) Turner Syndrome confirmed by chromosome analysis. For GHD, CRI, SHOX deficiency, Noonan syndrome, and PWS one of the following height more than 3 SDS below mean for age and gender, or height more than 2 SDS below mean with GV more than 1 SDS below mean, or GV over 1 year 2 SDS below mean. OR Diagnosis of an adult indication: A.) childhood- or adult-onset GHD confirmed by 2 standard GH stim tests (provide assay): 1 test must be insulin tolerance test (ITT) with blood glucose nadir less than 40 mg/dL (2.2 mmol/L). If contraindicated, use a standardized stim test (i.e. arginine plus GH releasing hormone [preferred], glucagon, arginine), B.) GHD with at least 1 other pituitary hormone deficiency and failed at least 1 GH stim test (ITT preferred), C.) GHD with panhypopituitarism (3 or more pituitary hormone deficiencies), D.) GHD with irreversible hypothalamic-pituitary structural lesions due to tumors, surgery or radiation of pituitary or hypothalamus region AND a subnormal IGF-1

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	(after at least 1 month off GH therapy) AND Objective evidence of GHD complications, such as: low bone density, increased visceral fat mass, or cardiovascular complications AND Completed linear growth (GV less than 2 cm/year) AND GH has been discontinued for at least 1 month (if previously receiving GH)
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an Endocrinologist or Nephrologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

HEMADY

Products Affected

- HEMADY

PA Criteria	Criteria Details
Exclusion Criteria	Systemic fungal infections
Required Medical Information	Diagnosis of multiple myeloma (MM) ,used in combination with other anti-myeloma drugs, and treatment regimen can not be supported by lower strengths of oral dexamethasone
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

HEPATITIS B

Products Affected

- *adefovir dipivoxil*
- BARACLUDE ORAL SOLUTION
- *entecavir*
- VEMLIDY

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of chronic hepatitis B and all of the following 1.) Patient has evidence of viral replication, 2.) Patient has evidence of persistent elevations in serum aminotransferase (ALT or AST) or histologically active disease, and 3.) Patient is receiving anti-retroviral therapy if the patient has HIV co-infection
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist, hepatologist, or infectious disease specialist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

HEPATITIS C

Products Affected

- MAVYRET
- *sofosbuvir-velpatasvir*
- VOSEVI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of HCV genotype, subtype and quantitative HCV RNA (viral load) testing any time prior to therapy. Must document the following within 12 weeks of starting therapy: CBC, INR, hepatic function panel, and GFR. Must document cirrhosis status, prior treatment history (if any), and planned duration of treatment. All genotypes will require trial/failure, contraindication to, or intolerance to Mavyret or Sofosbuvir-Velpatasvir prior to the approval of Vosevi.
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist, hepatologist, or infectious disease specialist
Coverage Duration	Duration of approval per AASLD Guidelines
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

HUMIRA

Products Affected

- HUMIRA PEDIATRIC CROHNS START SUBCUTANEOUS PREFILLED SYRINGE KIT 80 MG/0.8ML, 80 MG/0.8ML & 40MG/0.4ML
- HUMIRA PEN SUBCUTANEOUS PEN-INJECTOR KIT
- HUMIRA PEN-CD/UC/HS STARTER
- HUMIRA PEN-PS/UV/ADOL HS START SUBCUTANEOUS PEN-INJECTOR KIT 40 MG/0.8ML
- HUMIRA PEN-PSOR/UEVIT STARTER
- HUMIRA SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Moderate to severe rheumatoid arthritis, B.) Moderate to severe polyarticular juvenile idiopathic arthritis, C.) Psoriatic arthritis, D.) Ankylosing spondylitis, E.) Moderate to severe chronic plaque psoriasis in patients who are candidates for systemic therapy or phototherapy and when other systemic therapies are medically less appropriate, F.) Moderate to severe Crohn's disease in patients who have had an inadequate response to conventional therapy, G.) Moderate to severe ulcerative colitis in patients who have had an inadequate response to immunosuppressants (e.g. corticosteroids, azathioprine), H.) Non-infectious uveitis (including intermediate, posterior, and panuveitis), or I.) Moderate to severe hidradenitis suppurativa
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	Screening for latent tuberculosis infection is required prior to initiation of treatment
Indications	All Medically-accepted Indications.

H1587_PA21_C

Formulary ID: 21331 Version 10

Last Updated: 04/30/2021

Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

PA Criteria	Criteria Details
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

IBRANCE

Products Affected

- IBRANCE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Advanced or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer used in combination with fulvestrant and disease has progressed following endocrine therapy, or B.) Advanced or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer used in combination with an aromatase inhibitor in postmenopausal women or men
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

ICLUSIG

Products Affected

- ICLUSIG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) in adult patients who are T315I-positive or for whom no other tyrosine kinase inhibitor therapy is indicated, B.) Chronic phase, chronic myeloid leukemia (CML) in adult patients with resistance or intolerance to at least two prior kinase inhibitors, or C.) Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in adult patients who are T315I-positive or for whom no other tyrosine kinase inhibitor therapy is indicated
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

IDHIFA

Products Affected

- IDHIFA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase 2 (IDH2) mutation as detected by an FDA approved test
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

IMATINIB

Products Affected

- imatinib mesylate*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), B.) Ph+ acute lymphoblastic leukemia (ALL), C.) Gastrointestinal stromal tumor (GIST) where patient has documented c-KIT (CD117) positive unresectable or metastatic malignant GIST or patient had resection of c-KIT positive GIST and imatinib will be used as an adjuvant therapy, D.) Dermatofibrosarcoma protuberans that is unresectable, recurrent, or metastatic, E.) Hypereosinophilic syndrome or chronic eosinophilic leukemia, F.) Myelodysplastic syndrome or myeloproliferative disease associated with platelet-derived growth factor receptor gene re-arrangements, or G.) Aggressive systemic mastocytosis without the D816V c-KIT mutation or with c-KIT mutational status unknown
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

IMBRUVICA

Products Affected

- IMBRUVICA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Mantle cell lymphoma (MCL) and patient has received at least one prior therapy, B.) Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL), C.) Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion, D.) Waldenstrom's macroglobulinemia (WM), E.) Marginal zone lymphoma (MZL) and patient requires systemic therapy and has received at least one prior anti-CD20-based therapy, or F.) Chronic graft vs host disease (cGVHD) after failure of a least one first-line corticosteroid therapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

INCRELEX

Products Affected

- INCRELEX

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following: A.) active or suspected malignancy, B.) use for growth promotion in patients with closed epiphyses, C.) Intravenous administration
Required Medical Information	Prescribed for treatment of growth failure in pediatric patient AND patient has diagnosis of one of the following A.) Severe primary insulin-like growth factor-1 (IGF-1) deficiency, or B.) Growth hormone (GH) gene deletion and patient has developed neutralizing antibodies to GH
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

INLYTA

Products Affected

- INLYTA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Advanced renal cell carcinoma and patient failed one or more systemic therapies for renal cell carcinoma (e.g., sunitinib-, bevacizumab-, temsirolimus-, or cytokine-containing regimens), or B.) Advanced renal cell carcinoma and used as first-line therapy in combination with avelumab or pembrolizumab
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

INQOVI

Products Affected

- INQOVI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

INREBIC

Products Affected

- INREBIC

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

INTRON A

Products Affected

- INTRON A

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Autoimmune hepatitis, B.) Decompensated liver disease
Required Medical Information	Diagnosis of one of the following A.) Hairy cell leukemia, B.) Condylomata acuminata involving external surfaces to the genital or perianal areas, C.) AIDS-related Kaposi's sarcoma, D.) Clinically aggressive follicular lymphoma and the medication will be used concurrently with anthracycline-containing chemotherapy or is not a candidate for anthracycline-containing chemotherapy, E.) Malignant melanoma and the request for coverage is within 56 days of surgery and the patient is at high risk of disease recurrence, F.) Chronic hepatitis B with compensated liver disease and patient has evidence of hepatitis B viral replication and patient has been serum hepatitis B surface antigen-positive for at least 6 months, or G.) Chronic hepatitis C with compensated liver disease and is receiving combination therapy with ribavirin, unless ribavirin is contraindicated, and the medication will not be used as part of triple therapy with a protease inhibitor and patient has a clinical reason for not using peginterferon
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Condylomata: 3 months, HBV E antigen positive and Kaposi sarcoma: 16 weeks, Other: 12 months
Other Criteria	B vs D determination required per CMS guidance
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

IRESSA

Products Affected

- IRESSA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of metastatic non-small cell lung cancer (NSCLC) and must meet both of the following 1.) tumor has epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility, AND 2.) Used as first-line treatment
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

ISTURISA

Products Affected

- ISTURISA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of Cushing's disease in patients for whom pituitary surgery is not an option or has not been curative
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

ITRACONAZOLE

Products Affected

- *itraconazole oral*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Ventricular dysfunction (e.g., congestive heart failure (CHF) or history of CHF), B.) Concurrent therapy with a CYP3A4 substrate (e.g., methadone, lovastatin, simvastatin, etc.)
Required Medical Information	Diagnosis of one of the following A.) Systemic fungal infection (e.g., aspergillosis, histoplasmosis, blastomycosis), or B.) Onychomycosis confirmed by one of the following positive potassium hydroxide (KOH) preparation, fungal culture, or nail biopsy
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	6 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

ITRACONAZOLE SOLN

Products Affected

- *itraconazole oral*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Ventricular dysfunction (e.g., congestive heart failure (CHF) or history of CHF), B.) Concurrent therapy with a CYP3A4 substrate (e.g., methadone, lovastatin, simvastatin, etc.)
Required Medical Information	Diagnosis of candidiasis (esophageal or oropharyngeal) that is refractory to treatment with fluconazole
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	6 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

IVIG

Products Affected

- GAMMAGARD INJECTION SOLUTION 2.5 GM/25ML
- GAMMAGARD S/D LESS IGA
- GAMMAKED INJECTION SOLUTION 1 GM/10ML
- GAMMAPLEX INTRAVENOUS SOLUTION 10 GM/100ML, 10 GM/200ML, 20 GM/200ML, 5 GM/50ML
- GAMUNEX-C INJECTION SOLUTION 1 GM/10ML
- OCTAGAM INTRAVENOUS SOLUTION 1 GM/20ML, 2 GM/20ML
- PRIVIGEN INTRAVENOUS SOLUTION 20 GM/200ML

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) IgA deficiency with antibody formation and a history of hypersensitivity, or B.) History of anaphylaxis or severe systemic reaction to human immune globulin
Required Medical Information	Supporting statement of diagnosis from the physician
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	B vs D determination required per CMS guidance
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

JAKAFI

Products Affected

- JAKAFI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis, B.) Polycythemia vera AND patient has had an inadequate response to or is intolerant of hydroxyurea, OR C.) Acute graft versus host disease AND disease is refractory to steroid therapy
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	6 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

JUXTAPID

Products Affected

- JUXTAPID ORAL CAPSULE 10 MG, 20 MG, 30 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Moderate to severe liver impairment or active liver disease including unexplained persistent abnormal liver function tests, B.) Pregnancy, or C.) Concomitant use with strong or moderate CYP3A4 inhibitors
Required Medical Information	Diagnosis of HoFH as confirmed by one of the following A.) Genetic confirmation of 2 mutations in the LDL receptor, ApoB, PCSK9, or LDL receptor adaptor protein 1 (LDLRAP1 or ARH), or B.) Both of the following 1.) Either untreated LDL-C greater than 500 mg/dL or treated LDL-C greater than 300 mg/dL, and 2.) Either xanthoma before 10 years of age or evidence of heterozygous FH in both parents
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Initial: 6 months, Renewal: 12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

JYNARQUE

Products Affected

- JYNARQUE ORAL TABLET THERAPY
PACK

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following: A.) Use in patients unable to sense or respond to thirst, B.) Anuria, C.) History, signs, or symptoms of significant liver impairment or injury, D.) Uncorrected abnormal blood sodium concentrations, E.) Uncorrected urinary outflow obstruction, F.) Hypovolemia, G) Concomitant use of strong CYP 3A Inhibitors (eg. clarithromycin, ketoconazole, ritonavir)
Required Medical Information	Diagnosis of autosomal dominant polycystic kidney disease (ADPKD)
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

KALYDECO

Products Affected

- KALYDECO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of cystic fibrosis (CF) and the patient has 1 mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or prescribing practitioner is from a CF center accredited by the Cystic Fibrosis Foundation
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

KESIMPTA

Products Affected

- KESIMPTA

PA Criteria	Criteria Details
Exclusion Criteria	Active Hepatitis B infection
Required Medical Information	Diagnosis of one of the following A.) Relapsing forms of multiple sclerosis (e.g., clinically isolated syndrome, relapsing-remitting MS, active secondary progressive disease, or progressive-relapsing MS), or B.) Patient has experienced a first clinical episode and has MRI features consistent with multiple sclerosis
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

**H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021**

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

KISQALI

Products Affected

- KISQALI (200 MG DOSE)
- KISQALI (400 MG DOSE)
- KISQALI (600 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Hormone receptor (HR)-positive, HER-2 negative advanced or metastatic breast cancer in pre/perimenopausal or postmenopausal women and used in combination with an aromatase inhibitor, or B.) Hormone receptor (HR)-positive, HER-2 negative advanced or metastatic breast cancer in postmenopausal women and used in combination with fulvestrant
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

KISQALI FEMARA

Products Affected

- KISQALI FEMARA (400 MG DOSE)
- KISQALI FEMARA (600 MG DOSE)
- KISQALI FEMARA(200 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of hormone receptor (HR)-positive, HER-2 negative advanced or metastatic breast cancer in pre/perimenopausal or postmenopausal women
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

KORLYM

Products Affected

- KORLYM

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) pregnancy, B.) coadministration with simvastatin, lovastatin, or CYP3A substrates with narrow therapeutic ranges, C.) concomitant treatment with systemic corticosteroids for serious medical conditions or illnesses, D.) history of unexplained vaginal bleeding, E.) endometrial hyperplasia with atypia or endometrial carcinoma
Required Medical Information	Diagnosis of endogenous Cushing syndrome in patients with type 2 diabetes mellitus or glucose intolerance and both of the following 1.) Used to control hyperglycemia secondary to hypercortisolism, AND 2.) Patient has failed or is not a candidate for surgery
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

KOSELUGO

Products Affected

- KOSELUGO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of neurofibromatosis type 1 (NF1) in a patient who has symptomatic, inoperable plexiform neurofibromas (PN)
Age Restrictions	2 years of age to 17 years of age
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

LAPATINIB

Products Affected

- *lapatinib ditosylate*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of advanced or metastatic breast cancer with tumors that overexpress human epidermal growth factor receptor 2 (HER2) AND meets one of the following A.) Used in combination with capecitabine in a patient who has received prior therapy including an anthracycline, a taxane, and trastuzumab, OR B.) Used in combination with letrozole in a postmenopausal female for whom hormonal therapy is indicated
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

LENVIMA

Products Affected

- LENVIMA (10 MG DAILY DOSE)
- LENVIMA (12 MG DAILY DOSE)
- LENVIMA (14 MG DAILY DOSE)
- LENVIMA (18 MG DAILY DOSE)
- LENVIMA (20 MG DAILY DOSE)
- LENVIMA (24 MG DAILY DOSE)
- LENVIMA (4 MG DAILY DOSE)
- LENVIMA (8 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer, B.) Advanced renal cell carcinoma, in combination with everolimus, following one prior anti-angiogenic therapy, C.) Unresectable hepatocellular carcinoma, first-line therapy, D.) Advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient, in combination with pembrolizumab, when disease has progressed following prior systemic therapy AND patient is not a candidate for curative surgery or radiation
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

LEUKINE

Products Affected

- LEUKINE INJECTION SOLUTION RECONSTITUTED

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Patient has undergone allogeneic or autologous bone marrow transplant (BMT) and engraftment is delayed or failed, B.) Patient is undergoing autologous peripheral-blood progenitor cell transplant to mobilize progenitor cells for collection by leukapheresis, C.) Medication will be used for myeloid reconstitution after an autologous or allogeneic BMT, D.) Patient has acute myeloid leukemia and administration will be after completion of induction chemotherapy, E.) Hematopoietic subsyndrome of acute radiation syndrome (H-ARS) or F.) Autologous peripheral blood stem cell transplant, Following myeloablative chemotherapy.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

LEUPROLIDE

Products Affected

- ELIGARD
- *leuprolide acetate injection*
- LUPRON DEPOT (1-MONTH)
- LUPRON DEPOT (3-MONTH)
- LUPRON DEPOT (4-MONTH)
- LUPRON DEPOT (6-MONTH)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Advanced or metastatic prostate cancer and patient has failed or is intolerant to Eligard (7.5 mg 1-month, 22.5 mg 3-month, 30 mg 4-month, & 45 mg 6-month depots only), B.) Endometriosis (3.75 mg 1-month & 11.25 mg 3-month depots only), C.) Anemia due to uterine leiomyomata (Fibroids) (3.75 mg 1-month & 11.25 mg 3-month depots only) and patient is preoperative, or D.) Central precocious puberty (idiopathic or neurogenic) in children
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	B vs D determination required per CMS guidance
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

LIDOCAINE EXT

Products Affected

- *lidocaine external ointment 5 %*
- *lidocaine-prilocaine external cream*
- *lidocaine hcl external solution*

PA Criteria	Criteria Details
Exclusion Criteria	Amide hypersensitivity
Required Medical Information	For topical anesthesia of skin and mucous membranes
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	B vs D determination required per CMS guidance
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

LIDOCAINE PATCH

Products Affected

- *lidocaine external patch 5 %*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Pain associated with diabetic neuropathy, B.) Pain associated with cancer-related neuropathy, C.) Post-herpetic neuralgia, D.) Back pain, or E.) Osteoarthritis of the knee or hip
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

LONSURF

Products Affected

- LONSURF

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Metastatic colorectal cancer, previously treated with fluoropyrimidine, oxaliplatin, and irinotecan-based regimens, an anti-VEGF therapy, and if RAS wild-type, an anti-EGFR therapy, or B.) Metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least 2 prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan and if appropriate, HER2/neu-targeted therapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

LORBRENA

Products Affected

- LORBRENA

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with strong CYP3A4 inducers
Required Medical Information	Diagnosis of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) and one of the following 1.) Disease has progressed on alectinib as the first ALK inhibitor therapy for metastatic disease, OR 2.) Disease has progressed on ceritinib as the first ALK inhibitor therapy for metastatic disease, OR 3.) Disease has progressed on crizotinib AND at least 1 other ALK inhibitor for metastatic disease
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

LUPKYNIS

Products Affected

- LUPKYNIS

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin)
Required Medical Information	Initial: Diagnosis of systemic lupus erythematosus (SLE) with active lupus nephritis (LN) Classes III, IV, V (alone or in combination), and all of the following: 1.) Baseline renal function of 45 mL/min/1.73 m ² or greater, 2.) Will be used in combination with a background immunosuppressive therapy regimen (e.g. mycophenolate, oral steroids, etc). Renewal: Improvement in urine protein to creatinine ratio (UPCR) (i.e. 0.5 mg/mg or less) AND estimated glomerular filtration rate (eGFR) of 60 mL/min/1.73 m ² or greater, or no confirmed decrease from baseline in eGFR of greater than 20%
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a rheumatologist or nephrologist
Coverage Duration	Initial: 12 months, Renewal: 12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

LYNPARZA

Products Affected

- LYNPARZA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	<p>Diagnosis of one of the following A.) HER2-negative, deleterious or suspected deleterious germline BRCA mutated metastatic breast cancer AND patient has been previously treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, B.) Advanced ovarian cancer with known or suspected BRCA mutation as detected by an FDA-approved test AND patient has trial and failure, contraindication, or intolerance to 3 or more prior lines of chemotherapy, C.) Recurrent epithelial ovarian cancer, recurrent fallopian tube cancer, or recurrent primary peritoneal cancer AND used for maintenance treatment in patients who are in complete or partial response to platinum-based chemotherapy (e.g. cisplatin, carboplatin), D.) Deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients with complete or partial response to first-line platinum-based chemotherapy, E.) Deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma and disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen, F.) Advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA-mutation, and/or genomic instability. Used in combination with bevacizumab for maintenance treatment., or G.) Deleterious or suspected deleterious germline or somatic homologous recombination repair gene mutated metastatic castration-resistant prostate cancer in patients who have progressed following prior treatment with enzalutamide or abiraterone.</p>
Age Restrictions	None
Prescriber Restrictions	None

H1587_PA21_C

Formulary ID: 21331 Version 10

Last Updated: 04/30/2021

Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

PA Criteria	Criteria Details
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

MATULANE

Products Affected

- MATULANE

PA Criteria	Criteria Details
Exclusion Criteria	Inadequate marrow reserve
Required Medical Information	Diagnosis of Hodgkin's Disease, Stages III and IV and used in combination with other anticancer drugs
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

MAYZENT

Products Affected

- MAYZENT
- MAYZENT STARTER PACK

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) CYP2C9*3/*3 genotype, B.) In the last 6 months experienced myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, Class III-IV heart failure, or C.) Presence of Mobitz type II second-degree, third-degree AV block, or sick sinus syndrome, unless patient has a functioning pacemaker
Required Medical Information	Diagnosis of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease and the following A.) Patients with relapsing forms of multiple sclerosis have history of/or contraindication to Avonex, Betaseron, Copaxone, Gilenya, or Dimethyl Fumarate (Tecfidera)
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

MEKINIST

Products Affected

- MEKINIST

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and used in combination with dabrafenib and no locoregional treatment options, B.) Malignant melanoma with lymph node involvement and following complete resection with BRAF V600E or V600K mutations and used in combination with dabrafenib, C.) Unresectable or metastatic malignant melanoma with BRAF V600E or V600K mutations and used in combination with dabrafenib or as monotherapy , or D.) Metastatic non-small cell lung cancer, with BRAF V600E mutation, in combination with dabrafenib
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

MEKTOVI

Products Affected

- MEKTOVI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of unresectable or metastatic malignant melanoma with documented BRAF V600E or V600K mutation as detected by an FDA approved test AND used in combination with encorafenib
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

METHOXSALLEN

Products Affected

- *methoxsalen rapid*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Aphakia, B.) Melanoma or a history of melanoma, C.) Invasive squamous cell carcinomas, or D.) History of a light sensitive disease/skin photosensitivity disorder such systemic lupus erythematosus (SLE), porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum or albinism
Required Medical Information	Diagnosis of one of the following A.) Psoriasis, B.) Cutaneous T-cell lymphoma, or C.) Vitiligo
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist, immunologist, or dermatologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

MIGLUSTAT

Products Affected

- *miglustat*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of mild to moderate type 1 Gaucher disease and patient is not a candidate for enzyme replacement therapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

MS INTERFERONS

Products Affected

- AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT
- AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT
- BETASERON SUBCUTANEOUS KIT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Relapsing forms of multiple sclerosis (e.g., clinically isolated syndrome, relapsing-remitting MS, active secondary progressive disease, or progressive-relapsing MS), or B.) Patient has experienced a first clinical episode and has MRI features consistent with multiple sclerosis
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

NATPARA

Products Affected

- NATPARA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of hypoparathyroidism and used to control hypocalcemia
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

NERLYNX

Products Affected

- NERLYNX

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Early stage HER2-positive breast cancer and used following adjuvant trastuzumab therapy, or B.) Advanced or metastatic HER2-positive breast cancer, used in combination with capecitabine, AND patient has received 2 or more prior anti-HER2-based regimens in the metastatic setting
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

NEXAVAR

Products Affected

- NEXAVAR

PA Criteria	Criteria Details
Exclusion Criteria	Squamous cell lung cancer being treated with carboplatin and paclitaxel
Required Medical Information	Diagnosis of one of the following A.) Advanced renal cell carcinoma, B.) Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment, or C.) Unresectable hepatocellular carcinoma
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

NINLARO

Products Affected

- NINLARO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of multiple myeloma, used in combination with lenalidomide and dexamethasone, AND patient has history of at least 1 prior therapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

NITISINONE

Products Affected

- *nitisinone*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of hereditary tyrosinemia type 1
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

NORTHERA

Products Affected

- NORTHERA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (e.g., Parkinson disease, multiple system atrophy, pure autonomic failure), dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

NOXAFIL

Products Affected

- NOXAFIL ORAL SUSPENSION

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Concomitant treatment with sirolimus, B.) Concomitant use of CYP3A4 substrates that prolong QT interval (pimozide, quinidine), C.) Concomitant use of HMG-CoA Reductase inhibitors primarily metabolized through CYP3A4, or D.) Concomitant use of ergot alkaloids
Required Medical Information	Diagnosis of one of the following A.) Oropharyngeal candidiasis, or B.) Patient is severely immunocompromised and requires prophylaxis of invasive aspergillosis or candidiasis due to high risk of infection
Age Restrictions	13 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

NUBEQA

Products Affected

- NUBEQA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of non-metastatic, castration-resistant prostate cancer
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or urologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

NUCALA

Products Affected

- NUCALA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Severe asthma with eosinophilic phenotype, B.) Eosinophilic granulomatosis with polyangiitis (EGPA), or C.) Hypereosinophilic syndrome lasting at least 6 months without an identifiable non-hematologic secondary cause
Age Restrictions	6 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an allergist, immunologist, pulmonologist, or rheumatologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

NUEDEXTA

Products Affected

- NUEDEXTA

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) History of prolonged QT interval, congenital long QT syndrome or Torsades de pointes, B.) Heart failure, C.) Complete AV block without an implanted pacemaker or high risk of complete AV block, D.) Concomitant use with quinidine, quinine, mefloquine, or drugs that prolong QT interval and are metabolized by CYP2D6 (e.g., thioridazine, pimozide), E.) Concomitant use with MAOIs or within 14 days of MAOI therapy
Required Medical Information	Diagnosis of pseudobulbar affect
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

OCTREOTIDE

Products Affected

- *octreotide acetate injection solution 100 mcg/ml, 1000 mcg/ml, 200 mcg/ml, 50 mcg/ml, 500 mcg/ml*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Acromegaly and patient has inadequate response to or is ineligible for surgery, radiation, or bromocriptine mesylate, or B.) Metastatic carcinoid syndrome, or C.) Vasoactive intestinal peptide-secreting tumors (VIPomas) with associated diarrhea
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

ODOMZO

Products Affected

- ODOMZO

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy
Required Medical Information	Diagnosis of locally advanced basal cell carcinoma of the skin and one of the following A.) Cancer has recurred following surgery or radiation therapy, B.) Patient is not a candidate for surgery or radiation therapy.
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

OFEV

Products Affected

- OFEV

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Idiopathic pulmonary fibrosis (IPF), B.) Systemic sclerosis-associated interstitial lung disease (ILD), or C.) Chronic fibrosing interstitial lung disease with a progressive phenotype
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

ONUREG

Products Affected

- ONUREG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of acute myeloid leukemia (AML) used in maintenance treatment for adult patients who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

OPSUMIT

Products Affected

- OPSUMIT

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy
Required Medical Information	Diagnosis of pulmonary arterial hypertension (WHO Group I), confirmed by right heart catheterization or Doppler echocardiogram if patient is unable to undergo a right heart catheterization (e. g., patient is frail, elderly, etc.)
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or cardiologist
Coverage Duration	Initial: 6 months, Renewal: 12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

**H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021**

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

ORFADIN

Products Affected

- ORFADIN ORAL CAPSULE 20 MG
- ORFADIN ORAL SUSPENSION

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of hereditary tyrosinemia type 1
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

ORGOVYX

Products Affected

- ORGOVYX

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of advanced prostate cancer
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

ORKAMBI

Products Affected

- ORKAMBI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of cystic fibrosis (CF) with documented homozygous F508del mutation confirmed by FDA-approved CF mutation test
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or prescribing practitioner is from a CF center accredited by the Cystic Fibrosis Foundation
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

OSPHENA

Products Affected

- OSPHENA

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following: A.) Undiagnosed abnormal genital bleeding, B.) Known or suspected estrogen-dependent neoplasia, C.) Active deep vein thrombosis (DVT), pulmonary embolism (PE), or a history of these conditions, D.) Active arterial thromboembolic disease (eg. stroke, myocardial infarction) or a history of these conditions, or E.) Pregnancy
Required Medical Information	Diagnosis of one of the following A.) Moderate to severe dyspareunia due to vulvar and vaginal atrophy associated with menopause, or B.) Moderate to severe vaginal dryness due to vulvar and vaginal atrophy associated with menopause
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

OXANDROLONE

Products Affected

- *oxandrolone oral*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following: A.) Known or suspected carcinoma of the prostate or breast in males, B.) Carcinoma of the breast in females with hypercalcemia, C.) Pregnancy, D.) Nephrosis or nephrotic phase of nephritis, E.) Hypercalcemia
Required Medical Information	Diagnosis of one of the following A.) Bone pain associated with osteoporosis, B.) Protein catabolism associated with chronic corticosteroid administration, or C.) Used as adjunctive therapy to promote weight gain after weight loss associated with one of the following 1.) Extensive surgery, 2.) Chronic infections, 3.) Severe trauma, or 4.) Failure to gain or maintain at least 90% of ideal body weight without definite pathophysiologic reasons
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	3 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

PEGYLATED INTERFERON

Products Affected

- PEGASYS SUBCUTANEOUS SOLUTION

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Autoimmune hepatitis or other autoimmune condition known to be exacerbated by interferon, B.) Uncontrolled depression
Required Medical Information	Diagnosis of one of the following A.) Chronic hepatitis B infection, or B.) Chronic hepatitis C and required criteria will be applied consistent with current AASLD-IDSA guidance with compensated liver disease
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist, hepatologist, or infectious disease specialist
Coverage Duration	HBV: 12 months, HCV: based on current AASLD guidelines
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

**H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021**

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

PEMAZYRE

Products Affected

- PEMAZYRE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with confirmed fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist, gastroenterologist, or hepatologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

PENICILLAMINE

Products Affected

- *penicillamine oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Breastfeeding, B.) During Pregnancy (except for treatment of Wilson's disease), C.) Hypersensitivity to penicillamine products, D.) Penicillamine-related aplastic anemia/agranulocytosis, E.) Rheumatoid arthritis patients with history or evidence of renal insufficiency
Required Medical Information	Diagnosis of one of the following A.) Cystinuria, B.) Rheumatoid arthritis, or C.) Wilson's disease
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

PIQRAY

Products Affected

- PIQRAY (200 MG DAILY DOSE)
- PIQRAY (250 MG DAILY DOSE)
- PIQRAY (300 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of hormone receptor (HR) positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer AND must meet all of the following 1.) Used in combination with fulvestrant, AND 2.) Disease has progressed on or after an endocrine-based regimen, AND 3.) Patient is a male OR postmenopausal female
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

POMALYST

Products Affected

- POMALYST

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy
Required Medical Information	Diagnosis of one of the following A.) AIDS-related Kaposi sarcoma and patient has failure on highly active antiretroviral therapy (HAART), B.) Kaposi sarcoma in HIV-negative adults, or C.) Multiple myeloma and in combination with dexamethasone in adults who have received at least 2 prior therapies (including lenalidomide and a proteasome inhibitor) and have demonstrate disease progression on or within 60 days of completion of the last therapy
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

POSACONAZOLE

Products Affected

- *posaconazole*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Concomitant treatment with sirolimus, B.) Concomitant use of CYP3A4 substrates that prolong QT interval (pimozide, quinidine), C.) Concomitant use of HMG-CoA Reductase inhibitors primarily metabolized through CYP3A4, or D.) Concomitant use of ergot alkaloids
Required Medical Information	Diagnosis of one of the following A.) Patient is severely immunocompromised and requires prophylaxis of invasive aspergillosis due to high risk of infection, or B.) Patient is severely immunocompromised and requires prophylaxis of candidiasis due to high risk of infection
Age Restrictions	13 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

PROMACTA

Products Affected

- PROMACTA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Chronic idiopathic thrombocytopenic purpura (ITP), B.) Chronic hepatitis C infection associated thrombocytopenia, or C.) Severe aplastic anemia with insufficient response to immunosuppressive therapy or in combination with standard immunosuppressive therapy
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

QINLOCK

Products Affected

- QINLOCK

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of advanced gastrointestinal stromal tumor (GIST) and patient has received prior treatment with 3 or more kinase inhibitors, including imatinib
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

QUININE SULFATE

Products Affected

- *quinine sulfate oral*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following: A.) Prolongation of QT interval, B.) Glucose-6-phosphate dehydrogenase deficiency, C.) Myasthenia gravis, D.) Known hypersensitivity to mefloquine or quinidine, E.) Optic neuritis, F.) Diagnosis of Blackwater fever
Required Medical Information	Diagnosis of one of the following A.) uncomplicated Plasmodium falciparum malaria, B.) uncomplicated Plasmodium vivax malaria, or C.) babesiosis
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	1 month
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

RAVICTI

Products Affected

- RAVICTI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of urea cycle disorders
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

REGRANEX

Products Affected

- REGRANEX

PA Criteria	Criteria Details
Exclusion Criteria	Known neoplasm at the site of application
Required Medical Information	Diagnosis of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply
Age Restrictions	16 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

REPATHA

Products Affected

- REPATHA
- REPATHA SURECLICK
- REPATHA PUSHTRONEX SYSTEM

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) primary hyperlipidemia including heterozygous familial hypercholesterolemia (HeFH), B.) homozygous familial hypercholesterolemia, C.) established cardiovascular disease and myocardial infarction prophylaxis, stroke prophylaxis, or coronary revascularization prophylaxis is required, or D.) clinical atherosclerotic cardiovascular disease (CVD) as defined as one of the following 1.) acute coronary syndrome, 2.) history of myocardial infarction, 3.) stable/unstable angina, 4.) coronary or other arterial revascularization, 5.) stroke, 6.) transient ischemic stroke (TIA), or 7.) peripheral arterial disease presumed to be atherosclerotic region
Age Restrictions	13 years of age and older
Prescriber Restrictions	None
Coverage Duration	Initial: 2 months, Renewal: 12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

RETEVMO

Products Affected

- RETEVMO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Advanced or metastatic RET-mutant medullary thyroid cancer (MTC) in patients who require systemic therapy, B.) Metastatic RET fusion-positive non-small cell lung cancer (NSCLC), or C.) Advanced or metastatic RET fusion-positive thyroid cancer in patients who require systemic therapy and are refractory to radioactive iodine, if appropriate
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

REVLIMID

Products Affected

- REVLIMID

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy
Required Medical Information	Diagnosis of one of the following A.) Multiple myeloma and medication will be used in combination with dexamethasone, B.) Autologous hematopoietic stem-cell transplantation (HSCT) in multiple myeloma patients, C.) Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndrome (MDS) associated with a deletion 5q cytogenetic abnormality or without additional cytogenetic abnormalities, D.) Mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib, E.) Follicular lymphoma and used in combination with rituximab, or F.) Marginal zone lymphoma and used in combination with rituximab
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

RILUTEK

Products Affected

- *riluzole*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of amyotrophic lateral sclerosis (ALS)
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

RINVOQ

Products Affected

- RINVOQ

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of moderate to severe rheumatoid arthritis
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	Screening for latent tuberculosis infection is required prior to initiation of treatment
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

ROZLYTREK

Products Affected

- ROZLYTREK

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) ROS1-positive metastatic non-small cell lung cancer (NSCLC), or B.) Solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have either progressed following treatment or have no satisfactory alternative therapy
Age Restrictions	12 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

RUBRACA

Products Affected

- RUBRACA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Epithelial ovarian, fallopian tube, or primary peritoneal cancer with deleterious BRCA mutation (germline and/or somatic) as detected by an FDA-approved test and patient has been treated with 2 or more prior lines of chemotherapy, B.) Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, used as maintenance treatment, and patient is in complete or partial response to platinum-based chemotherapy, or C.) Deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer and patient has been treated with androgen receptor-directed therapy and a taxane-based chemotherapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

RYDAPT

Products Affected

- RYDAPT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) treatment naive FLT3 mutation-positive acute myelogenous leukemia (AML) and must be used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation therapy, or B.) systemic mastocytosis or mast cell leukemia
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

SAMSCA

Products Affected

- *tolvaptan*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following: A.) Diagnosis of Autosomal Dominant Polycystic Kidney Disease (ADPKD), B.) Urgent need to raise serum sodium acutely, C.) Inability to sense or appropriately respond to thirst, D.) Hypovolemic hyponatremia, E.) Concomitant use of strong CYP 3A Inhibitors (eg. clarithromycin, ketoconazole, ritonavir), F.) Anuria
Required Medical Information	Diagnosis of clinically significant hypervolemic or euvolemic hyponatremia (serum sodium less than 125 mEq/L or less marks hyponatremia that is symptomatic and has resisted correction with fluid restriction), including in patients with heart failure and syndrome of inappropriate antidiuretic hormone (SIADH)
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	1 month
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

SAPROPTERIN

Products Affected

- *sapropterin dihydrochloride*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of hyperphenylalaninemia (HPA) caused by tetrahydrobiopterin (BH4)-responsive phenylketonuria (PKU)
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Initial: 2 months, Renewal: 12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

SIGNIFOR

Products Affected

- SIGNIFOR

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of Cushing disease and patient has had inadequate response to or is not a candidate for surgery. For renewal: Documentation of a clinically meaningful reduction in 24-hour urinary free cortisol (UFC) levels or improvement in signs or symptoms of the disease
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Initial: 6 months, Renewal: 12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

SILDENAFIL

Products Affected

- sildenafil citrate oral tablet 20 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Nitrate therapy, including intermittent use
Required Medical Information	Diagnosis of pulmonary arterial hypertension (WHO Group I), confirmed by right heart catheterization or Doppler echocardiogram if patient is unable to undergo a right heart catheterization (e.g., patient is frail, elderly, etc.)
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or cardiologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

SIRTURO

Products Affected

- SIRTURO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet all of the following 1.) Diagnosis of pulmonary multidrug resistant tuberculosis (MDR-TB) and 2.) Used in combination with at least 3 other agents.
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an infectious disease specialist
Coverage Duration	24 weeks
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

SKYRIZI

Products Affected

- SKYRIZI (150 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of moderate to severe plaque psoriasis and patient is a candidate for systemic therapy or phototherapy
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	Screening for latent tuberculosis infection is required prior to initiation of treatment
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

**H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021**

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

SOLTAMOX

Products Affected

- SOLTAMOX

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Concomitant coumarin-type anticoagulant therapy, B.) history of thromboembolic disease such as DVT or PE
Required Medical Information	Diagnosis of breast cancer and documentation of inability to swallow tablet formulation
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

SOMAVERT

Products Affected

- SOMAVERT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of acromegaly and patient has had an inadequate response to or is ineligible for surgery or radiation therapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

SPRYCEL

Products Affected

- SPRYCEL

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, B.) Chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy, C.) Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy, D.) Newly diagnosed Ph+ ALL in combination with chemotherapy
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

STELARA

Products Affected

- STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML
- STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Moderate to severely active Crohn disease, B.) Moderate to severe plaque psoriasis, C.) Active psoriatic arthritis, or D.) Moderate to severe active ulcerative colitis
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	Screening for latent tuberculosis infection is required prior to initiation of treatment
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

**H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021**

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

STIVARGA

Products Affected

- STIVARGA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Metastatic colorectal cancer in patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan containing chemotherapy, anti-VEGF therapy, and if RAS wild type, anti-EGFR therapy, B.) Liver carcinoma in patients previously treated with sorafenib, or C.) Locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) after treatment with imatinib and sunitinib
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

SUNOSI

Products Affected

- SUNOSI

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Concomitant use of an MAOI, or B.) Use within 14 days of discontinuing an MAOI
Required Medical Information	Diagnosis of one of the following A.) narcolepsy with excessive daytime drowsiness and has trial of/or contraindication to modafinil or armodafinil, or B.) obstructive sleep apnea (OSA) with excessive daytime drowsiness and has trial of/or contraindication to modafinil or armodafinil
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

SUTENT

Products Affected

- SUTENT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Gastrointestinal stromal tumor after disease progression on or intolerance to imatinib, B.) Pancreatic neuroendocrine tumors in a patient with unresectable locally advanced or metastatic disease, C.) Advanced renal cell carcinoma, or D.) Renal cell carcinoma and used as adjuvant therapy following nephrectomy in patients who are at high risk for recurrence
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

SYMDEKO

Products Affected

- SYMDEKO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of cystic fibrosis (CF) and must meet one of the following 1.) Patient is homozygous for the F508del mutation, or 2.) Patient has at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor verified by an FDA-cleared CF mutation test
Age Restrictions	6 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or prescribing practitioner is from a CF center accredited by the Cystic Fibrosis Foundation
Coverage Duration	Initial: 6 months, Renewal: 12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

SYMLIN

Products Affected

- SYMLINPEN 120 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- SYMLINPEN 60 SUBCUTANEOUS SOLUTION PEN-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following: A.) Confirmed diagnosis of gastroparesis, B.) Hypoglycemia unawareness
Required Medical Information	Diagnosis of type 1 or type 2 diabetes mellitus and patient uses mealtime insulin therapy and has failed to achieve desired glucose control
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

SYNAREL

Products Affected

- SYNAREL

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) pregnancy, B.) breastfeeding, C.) undiagnosed abnormal vaginal bleeding
Required Medical Information	Diagnosis of one of the following A.) Central precocious puberty, or B.) Endometriosis
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

**H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021**

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

SYNRIBO

Products Affected

- SYNRIBO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of chronic or accelerated phase chronic myeloid leukemia (CML) and patient has tried and failed or has a contraindication or intolerance to at least 2 tyrosine kinase inhibitors
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

**H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021**

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

TABRECTA

Products Affected

- TABRECTA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of metastatic non-small cell lung cancer (NSCLC) in patients whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

TAFINLAR

Products Affected

- TAFINLAR

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Locally advanced or metastatic anaplastic thyroid carcinoma with BRAF V600E mutation, in combination with trametinib and no satisfactory locoregional treatment options, B.) Metastatic non-small cell lung cancer with BRAF V600E mutation, in combination with trametinib OR in patients previously treated as monotherapy, C.) Unresectable or metastatic malignant melanoma with BRAF V600E or V600K mutation
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

TAGRISSO

Products Affected

- TAGRISSO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R mutation and used as first line therapy, B.) Metastatic non-small cell lung cancer with T790M EGFR mutation (as confirmed by an FDA-approved test) AND whose disease has progressed on or after EGFR tyrosine kinase inhibitor therapy, or C.) Non-small cell lung cancer (NSCLC) with tumor epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations (as confirmed by an FDA-approved test) AND patient requires adjuvant therapy after tumor resection
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

TALZENNA

Products Affected

- TALZENNA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

TARGRETIN GEL

Products Affected

- TARGRETIN EXTERNAL

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of primary cutaneous T-cell lymphoma (CTCL Stage 1A/1B) and patient had an inadequate response, is intolerant to, or has a contraindication to at least one prior systemic therapy (e.g., corticosteroids) indicated for cutaneous manifestations of CTCL
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist/hematologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

TASIGNA

Products Affected

- TASIGNA

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following: A.) Long QT syndrome, B.) Uncorrected hypokalemia, C.) Uncorrected hypomagnesemia
Required Medical Information	Diagnosis of one of the following A.) Newly diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (CML), B.) Chronic phase or accelerated phase Philadelphia chromosome-positive CML in a patient resistant or intolerant to prior therapy that included imatinib, or C.) Chronic phase Philadelphia chromosome-positive CML in a patient resistant or intolerant to prior tyrosine-kinase inhibitor therapy
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

TAVALISSE

Products Affected

- TAVALISSE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of thrombocytopenia in patient with chronic idiopathic thrombocytopenic purpura (ITP) and an insufficient response to one previous treatment
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

TAZAROTENE

Products Affected

- *tazarotene external cream*
- TAZORAC EXTERNAL GEL
- TAZORAC EXTERNAL CREAM 0.05 %

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy
Required Medical Information	Diagnosis of one of the following A.) acne vulgaris and patient has trial with at least one generic topical acne product, or B.) stable moderate to severe plaque psoriasis with 20% or less body surface area involvement and patient has trial with at least one other topical psoriasis product (e.g., medium to high potency corticosteroid and/or vitamin D analogs)
Age Restrictions	12 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

TAZVERIK

Products Affected

- TAZVERIK

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Metastatic or locally advanced epithelioid sarcoma in patients not eligible for complete resection, B.) Relapsed or refractory follicular lymphoma in patients whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, or C.) Relapsed or refractory follicular lymphoma in patients who have no satisfactory alternative treatment options
Age Restrictions	16 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

TEFLARO

Products Affected

- TEFLARO

PA Criteria	Criteria Details
Exclusion Criteria	Known serious hypersensitivity to cephalosporin class
Required Medical Information	Diagnosis of one of the following A.) acute bacterial skin and skin structure infection and patient has documented culture and sensitivity to Teflaro, or B.) community acquired pneumonia and patient has documented culture and sensitivity to Teflaro
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	2 weeks
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

TEGSEDI

Products Affected

- TEGSEDI

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Platelet count less than 100,000 per microliter, B.) Urinary protein to creatinine ratio (UPCR) of 1000 mg/g or higher
Required Medical Information	Diagnosis of Polyneuropathy of hereditary transthyretin-mediated amyloidosis
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

TEPMETKO

Products Affected

- TEPMETKO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of metastatic non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping alterations
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

TESTOSTERONES

Products Affected

- *methyltestosterone oral*
- *testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml, 200 mg/ml (1 ml)*
- *testosterone enanthate intramuscular solution*
- *testosterone transdermal gel 10 mg/act (2%), 12.5 mg/act (1%), 20.25 mg/1.25gm (1.62%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%), 50 mg/5gm (1%)*
- *testosterone transdermal solution*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following: A.) Carcinoma of the breast (males only), B.) Known or suspected carcinoma of the prostate, C.) Pregnancy
Required Medical Information	Diagnosis of one of the following A.) Hypogonadotropic hypogonadism, B.) Inoperable metastatic breast cancer in women who are postmenopausal (testosterone enanthate), C.) Primary hypogonadism, or D.) Delayed puberty (testosterone enanthate). Diagnosis of hypogonadism must be confirmed by a low-for-age serum testosterone (total or free) level defined by the normal laboratory reference value
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

TETRABENAZINE

Products Affected

- *tetrabenazine*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Actively suicidal, B.) Untreated or inadequately treated depression, C.) Impaired hepatic function, D.) Concomitant use of monoamine oxidase inhibitors, E.) Concomitant use of reserpine or within 20 days of discontinuing reserpine
Required Medical Information	Diagnosis of chorea associated with Huntington's disease
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

**H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021**

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

THALOMID

Products Affected

- THALOMID

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy
Required Medical Information	Diagnosis of one of the following A.) Multiple myeloma that is newly diagnosed, or B.) Erythema nodosum leprosum (ENL)
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or infectious disease specialist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

TIBSOVO

Products Affected

- TIBSOVO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation (as detected by an FDA-approved test), or B.) acute myeloid leukemia (newly-diagnosed) with susceptible isocitrate dehydrogenase-1 mutation and meets one of the following 1.) Patient is 75 years of age or older, or 2.) Patient has comorbidities that preclude intensive induction chemotherapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

TIGLUTIK

Products Affected

- TIGLUTIK

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of amyotrophic lateral sclerosis (ALS)
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

TOPICAL RETINOIDS

Products Affected

- *adapalene external cream*
- *adapalene external gel*
- AVITA
- *tretinoin external cream*
- *tretinoin external gel 0.01 %, 0.025 %*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of mild to moderate acne vulgaris
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

TOREMIFENE

Products Affected

- *toremifene citrate*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following: A.) Acquired or congenital long QT syndrome, B.) Uncorrected hypokalemia, C.) Uncorrected hypomagnesemia
Required Medical Information	Diagnosis of metastatic breast cancer and patient must have previous inadequate response or intolerance to tamoxifen
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	6 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

TRELSTAR

Products Affected

- TRELSTAR MIXJECT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of advanced prostate cancer and used in palliative treatment
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

TRIENTINE

Products Affected

- CLOVIQUE
- *trientine hcl*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of Wilson's disease in patients that are intolerant to penicillamine
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

TRIKAFTA

Products Affected

- TRIKAFTA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of cystic fibrosis (CF) and patient has at least 1 F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene verified by an FDA-cleared CF mutation test
Age Restrictions	12 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or prescribing practitioner is from a CF center accredited by the Cystic Fibrosis Foundation
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

**H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021**

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

TUKYSA

Products Affected

- TUKYSA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of advanced unresectable or metastatic HER2-positive breast cancer (including brain metastases) in patients who have received one or more prior anti-HER2-based regimens in the metastatic setting and drug is being used in combination with trastuzumab and capecitabine
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

TURALIO

Products Affected

- TURALIO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

**H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021**

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

TYMLOS

Products Affected

- TYMLOS

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of postmenopausal osteoporosis and one of the following A.) osteoporotic fracture or multiple risk factors for fracture, or B.) previous trial of/or contraindication to bisphosphonate
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Initial: 12 months, Renewal: 12 months (Maximum 24 month treatment per patient lifetime)
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

VALCHLOR

Products Affected

- VALCHLOR

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of cutaneous T-cell lymphoma (stage IA and IB mycosis fungoides-type) and patient has received prior skin-directed therapy (e.g. Topical corticosteroids, phototherapy, or topical nitrogen mustard)
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

VARIZIG

Products Affected

- VARIZIG INTRAMUSCULAR SOLUTION

PA Criteria	Criteria Details
Exclusion Criteria	History of hypersensitivity (including anaphylaxis or severe systemic reaction) to immune globulin or any component of the preparation
Required Medical Information	Diagnosis of post-exposure varicella (chickenpox) infection prophylaxis
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	6 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

VENCLEXTA

Products Affected

- VENCLEXTA
- VENCLEXTA STARTING PACK

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with strong CYP3A inhibitor during the initial and titration phase in patients with CLL or SLL
Required Medical Information	Diagnosis of one of the following A.) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), or B.) Newly-diagnosed acute myeloid leukemia (AML) and used in combination with azacitidine, decitabine or low-dose cytarabine in patients 75 years or older or who have comorbidities that preclude use of intensive induction chemotherapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

VERQUVO

Products Affected

- VERQUVO

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use of other soluble guanylate cyclase (sGC) stimulators
Required Medical Information	Diagnosis of chronic heart failure (HF), NYHA Class II to IV and all of the following 1.) Left ventricular ejection fraction less than 45%, 2.) Previous hospitalization for HF within 6 months or outpatient IV diuretic treatment for HF within 3 months
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

VERZENIO

Products Affected

- VERZENIO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of advanced or metastatic, HER2-negative, hormone receptor-positive breast cancer AND one of the following: A.) For postmenopausal women must be used in combination with fulvestrant for the treatment of disease progression following endocrine therapy and patient has trial and failure or contraindication to Ibrance or Kisqali, B.) For premenopausal or perimenopausal women must be used in combination with fulvestrant for the treatment of disease progression following endocrine therapy and patient has trial and failure or contraindication to Ibrance, C.) Used as monotherapy for treatment of disease progression following endocrine therapy and patient has already received at least one prior chemotherapy regimen of Ibrance or Kisqali, D.) For postmenopausal women used as initial endocrine-based treatment in combination with an aromatase inhibitor and patient has trial and failure or contraindication to Kisqali or Ibrance, E.) For premenopausal or perimenopausal women used as initial endocrine-based treatment in combination with an aromatase inhibitor and patient has trial and failure or contraindication to Kisqali
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

VIGABATRIN

Products Affected

- *vigabatrin*
- VIGADRONE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Infantile spasms, or B.) Refractory complex partial seizures and the drug is being used as adjunctive therapy in patients who have responded inadequately to several alternative treatments
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

VITRAKVI

Products Affected

- VITRAKVI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of metastatic or surgically unresectable neurotrophic receptor tyrosine kinase (NTRK) gene fusion positive solid tumors and used in patients with unsatisfactory alternative treatments or who have progressed following treatment
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

VIZIMPRO

Products Affected

- VIZIMPRO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of metastatic non-small cell lung cancer with confirmed epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

VOTRIENT

Products Affected

- VOTRIENT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Advanced renal cell carcinoma, or B.) Advanced soft tissue sarcoma and patient received at least one prior chemotherapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

XALKORI

Products Affected

- XALKORI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive or ROS1-positive as detected by an FDA-approved test, or B.) Relapsed or refractory systemic anaplastic large cell lymphoma that is anaplastic lymphoma kinase (ALK) positive as detected by an FDA-approved test
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

XELJANZ

Products Affected

- XELJANZ
- XELJANZ XR

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Pending CMS Review
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	Screening for latent tuberculosis infection is required prior to initiation of treatment
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

XGEVA

Products Affected

- XGEVA

PA Criteria	Criteria Details
Exclusion Criteria	Hypocalcemia (calcium less than 8.0 mg/dL)
Required Medical Information	Diagnosis of one of the following A.) Bone metastases from a solid tumor and used for the prevention of skeletal related events, B.) Multiple myeloma and used for the prevention of skeletal related events, C.) Hypercalcemia of malignancy refractory to bisphosphonate therapy, or D.) Giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

XOLAIR

Products Affected

- XOLAIR

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Chronic idiopathic urticaria in patients who remain symptomatic despite H1 antihistamine therapy, B.) Moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms are inadequately controlled with inhaled corticosteroids, or C.) Nasal polyps in patients with inadequate response to nasal corticosteroids
Age Restrictions	6 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an allergist, dermatologist, immunologist, otolaryngologist, or pulmonologist
Coverage Duration	Initial: 6 months, Renewal: 12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

XOSPATA

Products Affected

- XOSPATA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

XPOVIO

Products Affected

- XPOVIO (100 MG ONCE WEEKLY)
- XPOVIO (40 MG ONCE WEEKLY)
- XPOVIO (40 MG TWICE WEEKLY)
- XPOVIO (60 MG ONCE WEEKLY)
- XPOVIO (60 MG TWICE WEEKLY)
- XPOVIO (80 MG ONCE WEEKLY)
- XPOVIO (80 MG TWICE WEEKLY)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Relapsed or refractory multiple myeloma being used in combination with dexamethasone in a patient who has received at least 4 prior therapies and is refractory to at least 2 proteasome inhibitors, at least 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody, B.) Relapsed or refractory diffuse large B-cell lymphoma (DLBCL, including from follicular lymphoma) in a patient who has received at least 2 lines of systemic therapy, or C.) Multiple myeloma being used in combination with bortezomib and dexamethasone in a patient who has received at least 1 prior therapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

XTANDI

Products Affected

- XTANDI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Castration-resistant prostate cancer, or B.) Metastatic, castration-sensitive prostate cancer
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or urologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

XYREM

Products Affected

- XYREM

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Concomitant treatment with sedative hypnotic agents, B.) Succinic semialdehyde dehydrogenase deficiency
Required Medical Information	Diagnosis of one of the following A.) narcolepsy with excessive daytime drowsiness and has trial of/or contraindication to modafinil or armodafinil, or B.) cataplexy and narcolepsy
Age Restrictions	7 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

XYWAV

Products Affected

- XYWAV

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Concomitant treatment with sedative hypnotic agents, B.) Succinic semialdehyde dehydrogenase deficiency
Required Medical Information	Diagnosis of one of the following A.) Narcolepsy with excessive daytime drowsiness and has trial of/or contraindication to modafinil or armodafinil, or B.) Cataplexy and narcolepsy
Age Restrictions	7 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

YONSA

Products Affected

- YONSA

PA Criteria	Criteria Details
Exclusion Criteria	Pregnancy
Required Medical Information	Diagnosis of metastatic, castration-resistant prostate cancer and use in combination with methylprednisolone
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or urologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

**H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021**

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

ZARXIO

Products Affected

- ZARXIO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Chemotherapy induced febrile neutropenia (prophylaxis), B.) Severe chronic neutropenia, C.) Patient is undergoing autologous peripheral-blood progenitor cell transplant to mobilize progenitor cells for collection by leukapheresis, or D.) Hematopoietic subsyndrome of acute radiation syndrome (H-ARS)
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

ZEJULA

Products Affected

- ZEJULA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and used as maintenance therapy in a patient who is in a complete or partial response to platinum-based chemotherapy, or B.) Advanced ovarian, fallopian tube, or primary peritoneal cancer and patient has been treated with 3 or more prior chemotherapy regimens, and cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, or genomic instability
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or gynecologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

**H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021**

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

ZELBORAF

Products Affected

- ZELBORAF

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Unresectable or metastatic melanoma and patient has positive BRAF-V600E mutation documented by an FDA-approved test, or B.) Erdheim-Chester disease and patient has documented BRAF V600 mutation
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

ZIEXTENZO

Products Affected

- ZIEXTENZO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of chemotherapy induced febrile neutropenia (prophylaxis)
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

ZOLINZA

Products Affected

- ZOLINZA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of primary cutaneous T-cell lymphoma (CTCL) in patients who have progressive, persistent or recurrent disease on or following two systemic therapies (e.g., bexarotene, romidepsin, etc)
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

ZYDELIG

Products Affected

- ZYDELIG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Chronic lymphocytic leukemia, used in combination with rituximab and patient has relapsed on at least one prior therapy, B.) Non-Hodgkins lymphoma (Follicular, B-Cell) and the patient has relapsed on at least two prior systemic therapies, or C.) Small lymphocytic lymphoma and the patient has relapsed on at least two prior systemic therapies
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
 Formulary ID: 21331 Version 10
 Last Updated: 04/30/2021
 Effective date: 05/01/2021

**Tribute Health Plan 2021 Formulary
Prior Authorization Criteria**

ZYKADIA

Products Affected

- ZYKADIA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

H1587_PA21_C
Formulary ID: 21331 Version 10
Last Updated: 04/30/2021
Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary

Prior Authorization Criteria

PART B VERSUS PART D

Products Affected

- ABELCET
- *acetylcysteine inhalation*
- *acyclovir sodium intravenous solution*
- *albuterol sulfate inhalation nebulization solution (2.5 mg/3ml) 0.083%, 0.63 mg/3ml, 1.25 mg/3ml, 2.5 mg/0.5ml*
- AMBISOME
- AMINOSYN-PF INTRAVENOUS SOLUTION 7 %
- *amphotericin b intravenous*
- *aprepitant oral capsule*
- AZASAN
- *azathioprine oral*
- *budesonide inhalation*
- *calcitonin (salmon)*
- *calcitriol oral*
- *cinacalcet hcl*
- CLINIMIX E/DEXTROSE (2.75/5)
- CLINIMIX E/DEXTROSE (4.25/10)
- CLINIMIX E/DEXTROSE (4.25/5)
- CLINIMIX E/DEXTROSE (5/15)
- CLINIMIX E/DEXTROSE (5/20)
- CLINIMIX/DEXTROSE (4.25/10)
- CLINIMIX/DEXTROSE (4.25/5)
- CLINIMIX/DEXTROSE (5/15)
- CLINIMIX/DEXTROSE (5/20)
- CLINISOL SF
- *cromolyn sodium inhalation*
- *cyclophosphamide oral capsule*
- *cyclosporine modified*
- *cyclosporine oral capsule*
- *diphtheria-tetanus toxoids dt*
- ENGERIX-B INJECTION
- ENVARUSUS XR
- *everolimus oral tablet 0.25 mg, 0.5 mg, 0.75 mg*
- GENGRAF ORAL CAPSULE 100 MG, 25 MG
- GENGRAF ORAL SOLUTION
- *granisetron hcl oral*
- HEPATAMINE
- IMOVAX RABIES
- INTRALIPID
- *ipratropium bromide inhalation*
- *ipratropium-albuterol*
- ISOLYTE-P IN D5W
- ISOLYTE-S
- *levalbuterol hcl inhalation*
- *methotrexate oral*
- *methotrexate sodium (pf) injection solution 50 mg/2ml*
- *methotrexate sodium injection solution 50 mg/2ml*
- *mycophenolate mofetil oral*
- *mycophenolate sodium*
- NEPHRAMINE
- NUTRILIPID
- *ondansetron*
- *ondansetron hcl injection*
- *ondansetron hcl oral*
- *paricalcitol oral*
- *pentamidine isethionate inhalation*
- PLASMA-LYTE 148
- PLASMA-LYTE A
- PLENAMINE
- PREMASOL INTRAVENOUS SOLUTION 10 %
- PROCALAMINE
- PROGRAF ORAL PACKET
- PROSOL
- PULMOZYME
- RABA VERT
- RECOMBIVAX HB
- SANDIMMUNE ORAL SOLUTION
- *sirolimus oral*
- *tacrolimus oral*

H1587_PA21_C

Formulary ID: 21331 Version 10

Last Updated: 04/30/2021

Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

- TDVAX
- TENIVAC
- *tobramycin inhalation nebulization solution 300 mg/5ml*
- TPN ELECTROLYTES INTRAVENOUS CONCENTRATE
- TRAVASOL
- TREXALL
- TROPHAMINE INTRAVENOUS SOLUTION 10 %
- VARUBI (180 MG DOSE)
- XATMEP
- ZORTRESS ORAL TABLET 1 MG

Details

This drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

Tribute Health Plan 2021 Formulary

Prior Authorization Criteria

Alphabetical Listing

A	
ABELCET.....	358
abiraterone acetate	1
acetylcysteine inhalation.....	358
acitretin	3
ACTIMMUNE.....	4
acyclovir sodium intravenous solution ...	358
adapalene external cream.....	309, 310, 311
adapalene external gel.....	309, 310, 311
adefovir dipivoxil.....	121, 122, 123
ADEMPAS	5, 6
AFINITOR DISPERZ.....	7
AFINITOR ORAL TABLET 10 MG .	91, 92
albuterol sulfate inhalation nebulization solution (2.5 mg/3ml) 0.083%, 0.63 mg/3ml, 1.25 mg/3ml, 2.5 mg/0.5ml ..	358
ALECENSA.....	9
ALKINDI SPRINKLE.....	10
alosetron hcl	12
ALUNBRIG.....	15
AMBISOME.....	358
ambrisentan	16
AMINOSYN-PF INTRAVENOUS SOLUTION 7 %	358
amphotericin b intravenous.....	358
APOKYN SUBCUTANEOUS SOLUTION CARTRIDGE.....	17, 18
aprepitant oral capsule	358
ARCALYST	19
ARIKAYCE.....	20
armodafinil	42
AURYXIA	21
AUSTEDO	22
AVITA	309, 310, 311
AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT.....	205, 206, 207, 208
AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT.....	205, 206, 207, 208
AYVAKIT	23
AZASAN	358
azathioprine oral.....	358
B	
BALVERSA	24
BARACLUDGE ORAL SOLUTION	121, 122, 123
BENLYSTA SUBCUTANEOUS.....	25, 26
BETASERON SUBCUTANEOUS KIT	205, 206, 207, 208
bexarotene	27
bosentan	28
BOSULIF.....	29
BRAFTOVI ORAL CAPSULE 75 MG ..	30, 31
BRUKINSA	32
budesonide inhalation	358
C	
CABOMETYX	33
calcitonin (salmon).....	358
calcitriol oral	358
CALQUENCE	35
CAPRELSA	36
CARBAGLU.....	37
CAYSTON.....	38
cinacalcet hcl.....	358
CINRYZE	39
CLINIMIX E/DEXTROSE (2.75/5).....	358
CLINIMIX E/DEXTROSE (4.25/10).....	358
CLINIMIX E/DEXTROSE (4.25/5).....	358
CLINIMIX E/DEXTROSE (5/15).....	358
CLINIMIX E/DEXTROSE (5/20).....	358
CLINIMIX/DEXTROSE (4.25/10)	358
CLINIMIX/DEXTROSE (4.25/5)	358
CLINIMIX/DEXTROSE (5/15)	358
CLINIMIX/DEXTROSE (5/20)	358
CLINISOL SF.....	358
clobazam	40
CLOVIQUE	316, 317

H1587_PA21_C

Formulary ID: 21331 Version 10

Last Updated: 04/30/2021

Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary

Prior Authorization Criteria

COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG	44, 45, 46	ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML	74, 75, 76, 77, 78
COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG .	44, 45, 46	ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE	74, 75, 76, 77, 78
COMETRIQ (60 MG DAILY DOSE)	44, 45, 46	ENBREL SUBCUTANEOUS SOLUTION RECONSTITUTED	74, 75, 76, 77, 78
COPAXONE SUBCUTANEOUS SOLUTION PREFILLED SYRINGE	114, 115	ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR ...	74, 75, 76, 77, 78
COPIKTRA.....	48	ENDARI	80
CORLANOR ORAL TABLET	49, 50	ENGERIX-B INJECTION.....	358
COSENTYX (300 MG DOSE).....	51, 52	ENSPRYNG	81
COSENTYX SENSOREADY (300 MG)	51, 52	entecavir	121, 122, 123
COTELLIC	53	ENTRESTO	82
cromolyn sodium inhalation	358	ENVARUSUS XR.....	358
cyclophosphamide oral capsule	358	EPIDIOLEX.....	83
cyclosporine modified.....	358	ERIVEDGE.....	87
cyclosporine oral capsule.....	358	ERLEADA	88
CYSTADROPS.....	54	erlotinib hcl	89
CYSTARAN	56	ESBRIET	90
D		everolimus oral tablet 0.25 mg, 0.5 mg, 0.75 mg	358
dalfampridine er	57	everolimus oral tablet 2.5 mg, 5 mg, 7.5 mg	91, 92
DAURISMO	59	EVRYSDI	93
deferasirox granules	60, 61	F	
deferasirox oral tablet	60, 61	FARYDAK	94
deferasirox oral tablet soluble.....	60, 61	febuxostat	95
deferiprone	62	fentanyl	98
DIACOMIT.....	63	fentanyl citrate buccal lozenge on a handle	96, 97
diclofenac sodium external gel 3 %	64, 65	FERRIPROX ORAL SOLUTION....	99, 100
dimethyl fumarate oral.....	66, 67	FERRIPROX ORAL TABLET 1000 MG	99, 100
dimethyl fumarate starter pack.....	66, 67	FINTEPLA.....	101
diphtheria-tetanus toxoids dt.....	358	FIRAZYR	102
DOJOLVI.....	68	FIRMAGON (240 MG DOSE)	103, 104, 105
dronabinol	69	FIRMAGON SUBCUTANEOUS SOLUTION RECONSTITUTED 80 MG	103, 104, 105
DUPIXENT.....	70	FORTEO SUBCUTANEOUS SOLUTION PEN-INJECTOR.....	106, 107
E		FYCOMPA	108
ELIGARD	183, 184, 185, 186		
EMGALITY	71, 72		
EMGALITY (300 MG DOSE)	71, 72		
EMSAM.....	73		
ENBREL MINI.....	74, 75, 76, 77, 78		

H1587_PA21_C

Formulary ID: 21331 Version 10

Last Updated: 04/30/2021

Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary

Prior Authorization Criteria

G

GAMMAGARD INJECTION SOLUTION
2.5 GM/25ML.... 152, 153, 154, 155, 156,
157

GAMMAGARD S/D LESS IGA... 152, 153,
154, 155, 156, 157

GAMMAKED INJECTION SOLUTION 1
GM/10ML... 152, 153, 154, 155, 156, 157

GAMMAPLEX INTRAVENOUS
SOLUTION 10 GM/100ML, 10
GM/200ML, 20 GM/200ML, 5
GM/50ML... 152, 153, 154, 155, 156, 157

GAMUNEX-C INJECTION SOLUTION 1
GM/10ML... 152, 153, 154, 155, 156, 157

GATTEX..... 109

GAVRETO 110

GENGRAF ORAL CAPSULE 100 MG, 25
MG 358

GENGRAF ORAL SOLUTION..... 358

GILENYA ORAL CAPSULE 0.5 MG.. 111,
112

GILOTRIF 113

glatiramer acetate 114, 115

GOCOVRI 116

granisetron hcl oral 358

H

HEMADY..... 120

HEPATAMINE..... 358

HUMIRA PEDIATRIC CROHNS START
SUBCUTANEOUS PREFILLED
SYRINGE KIT 80 MG/0.8ML, 80
MG/0.8ML & 40MG/0.4ML 126, 127,
128, 129, 130, 131, 132, 133

HUMIRA PEN SUBCUTANEOUS PEN-
INJECTOR KIT . 126, 127, 128, 129, 130,
131, 132, 133

HUMIRA PEN-CD/UC/HS STARTER 126,
127, 128, 129, 130, 131, 132, 133

HUMIRA PEN-PS/UV/ADOL HS START
SUBCUTANEOUS PEN-INJECTOR
KIT 40 MG/0.8ML 126, 127, 128, 129,
130, 131, 132, 133

HUMIRA PEN-PSOR/UEVEIT STARTER
..... 126, 127, 128, 129, 130, 131, 132, 133

HUMIRA SUBCUTANEOUS PREFILLED
SYRINGE KIT 10 MG/0.1ML, 20
MG/0.2ML, 40 MG/0.4ML, 40
MG/0.8ML. 126, 127, 128, 129, 130, 131,
132, 133

I

IBRANCE..... 134

ICLUSIG..... 135

IDHIFA 136

imatinib mesylate 137, 138

IMBRUVICA..... 139

IMOVAX RABIES 358

INCRELEX..... 140

INLYTA..... 141

INQOVI 142

INREBIC..... 143

INTRALIPID 358

INTRON A..... 144, 145

ipratropium bromide inhalation 358

ipratropium-albuterol 358

IRESSA..... 146

ISOLYTE-P IN D5W 358

ISOLYTE-S 358

ISTURISA..... 147

itraconazole oral..... 148, 150

J

JAKAFI..... 159

JUXTAPID ORAL CAPSULE 10 MG, 20
MG, 30 MG, 5 MG 160, 161

JYNARQUE ORAL TABLET THERAPY
PACK..... 162, 163

K

KALYDECO..... 164

KESIMPTA..... 165

KISQALI (200 MG DOSE)..... 166, 167

KISQALI (400 MG DOSE)..... 166, 167

KISQALI (600 MG DOSE)..... 166, 167

KISQALI FEMARA (400 MG DOSE) . 168,
169, 170

KISQALI FEMARA (600 MG DOSE) . 168,
169, 170

H1587_PA21_C

Formulary ID: 21331 Version 10

Last Updated: 04/30/2021

Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

KISQALI FEMARA(200 MG DOSE) .. 168, 169, 170	LUPRON DEPOT (6-MONTH).... 183, 184, 185, 186
KORLYM 171	LYNPARZA ORAL TABLET..... 195, 196
KOSELUGO 172	M
L	MATULANE 197
lapatinib ditosylate 173, 174	MAVYRET..... 124, 125
LENVIMA (10 MG DAILY DOSE) 175, 176, 177, 178, 179	MAYZENT 198, 199
LENVIMA (12 MG DAILY DOSE) 175, 176, 177, 178, 179	MAYZENT STARTER PACK..... 198, 199
LENVIMA (14 MG DAILY DOSE) 175, 176, 177, 178, 179	MEKINIST 200
LENVIMA (18 MG DAILY DOSE) 175, 176, 177, 178, 179	MEKTOVI 201
LENVIMA (20 MG DAILY DOSE) 175, 176, 177, 178, 179	methotrexate oral 358
LENVIMA (24 MG DAILY DOSE) 175, 176, 177, 178, 179	methotrexate sodium (pf) injection solution 50 mg/2ml 358
LENVIMA (4 MG DAILY DOSE) 175, 176, 177, 178, 179	methotrexate sodium injection solution 50 mg/2ml 359
LENVIMA (8 MG DAILY DOSE) 175, 176, 177, 178, 179	methoxsalen rapid 202, 203
LEUKINE INJECTION SOLUTION	methyltestosterone oral .. 298, 299, 300, 301, 302, 303
RECONSTITUTED 181, 182	miglustat..... 204
leuprolide acetate injection 183, 184, 185, 186	modafinil 42
levabuterol hcl inhalation..... 358	mycophenolate mofetil oral 359
lidocaine external ointment 5 % 187, 188, 189	mycophenolate sodium 359
lidocaine external patch 5 % 190, 191	N
lidocaine hcl external solution 187, 188, 189	NATPARA..... 209
lidocaine-prilocaine external cream 187, 188, 189	NEPHRAMINE 359
LONSURF 192	NERLYNX 210
LORBRENA 193	NEXAVAR..... 211
LUPKYNIS 194	NINLARO..... 212
LUPRON DEPOT (1-MONTH).... 183, 184, 185, 186	nitisinone..... 213
LUPRON DEPOT (3-MONTH).... 183, 184, 185, 186	NORTHERA..... 214
LUPRON DEPOT (4-MONTH).... 183, 184, 185, 186	NOXAFIL ORAL SUSPENSION.. 215, 216
	NUBEQA 217
	NUCALA 218
	NUEDEXTA..... 219
	NUTRILIPID 359
	O
	OCTAGAM INTRAVENOUS SOLUTION 1 GM/20ML, 2 GM/20ML 152, 153, 154, 155, 156, 157
	octreotide acetate injection solution 100 mcg/ml, 1000 mcg/ml, 200 mcg/ml, 50 mcg/ml, 500 mcg/ml 220, 221, 222
	ODOMZO 223

H1587_PA21_C

Formulary ID: 21331 Version 10

Last Updated: 04/30/2021

Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

OFEV	224	PROLASTIN-C INTRAVENOUS SOLUTION RECONSTITUTED... 13, 14
OMNITROPE SUBCUTANEOUS SOLUTION CARTRIDGE. 117, 118, 119		PROMACTA
OMNITROPE SUBCUTANEOUS SOLUTION RECONSTITUTED..... 117, 118, 119		PROSOL
ondansetron	359	PULMOZYME
ondansetron hcl injection	359	Q
ondansetron hcl oral.....	359	QINLOCK.....
ONUREG.....	225	quinine sulfate oral.....
OPSUMIT	226	R
ORFADIN ORAL CAPSULE 20 MG... 227, 228		RABAVERT
ORFADIN ORAL SUSPENSION.. 227, 228		RAVICTI
ORGOVYX.....	229	RECOMBIVAX HB
ORKAMBI.....	230	REGRANEX.....
OSPHERA	231	REPATHA
oxandrolone oral	232, 233	REPATHA PUSHTRONEX SYSTEM. 250, 251
P		REPATHA SURECLICK.....
paricalcitol oral	359	RETACRIT INJECTION SOLUTION 10000 UNIT/ML, 10000 UNIT/ML(1ML), 2000 UNIT/ML, 20000 UNIT/ML, 3000 UNIT/ML, 4000 UNIT/ML, 40000 UNIT/ML
PEGASYS SUBCUTANEOUS SOLUTION	234, 235	84, 85, 86
PEMAZYRE.....	236	RETEVMO
penicillamine oral tablet.....	237, 238	REVLIMID
pentamidine isethionate inhalation	359	riluzole
PIQRAY (200 MG DAILY DOSE)239, 240, 241		RINVOQ.....
PIQRAY (250 MG DAILY DOSE)239, 240, 241		ROZLYTREK.....
PIQRAY (300 MG DAILY DOSE)239, 240, 241		RUBRACA
PLASMA-LYTE 148.....	359	RYDAPT.....
PLASMA-LYTE A.....	359	S
PLENAMINE	359	SANDIMMUNE ORAL SOLUTION
POMALYST	242	sapropterin dihydrochloride
posaconazole	243	SIGNIFOR
PREMASOL INTRAVENOUS SOLUTION 10 %	359	sildenafil citrate oral tablet 20 mg ..
PRIVIGEN INTRAVENOUS SOLUTION 20 GM/200ML ... 152, 153, 154, 155, 156, 157		sirolimus oral
PROCALAMINE.....	359	SIRTURO
PROGRAF ORAL PACKET.....	359	SKYRIZI (150 MG DOSE)
		sofosbuvir-velpatasvir.....
		SOLTAMOX
		SOMAVERT.....
		SPRYCEL.....
		STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML
		271, 272, 273

H1587_PA21_C

Formulary ID: 21331 Version 10

Last Updated: 04/30/2021

Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 271, 272, 273	(1.62%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%), 50 mg/5gm (1%) 298, 299, 300, 301, 302, 303
STIVARGA	274
SUNOSI	275
SUTENT	276
SYMDEKO	277
SYMLINPEN 120 SUBCUTANEOUS SOLUTION PEN-INJECTOR... 278, 279, 280	testosterone transdermal solution... 298, 299, 300, 301, 302, 303
SYMLINPEN 60 SUBCUTANEOUS SOLUTION PEN-INJECTOR... 278, 279, 280	tetrabenazine
SYMPAZAN.....	305
SYNAREL	306
SYNRIBO	307
T	TIGLUTIK.....
TABRECTA	308
tacrolimus oral	tobramycin inhalation nebulization solution 300 mg/5ml
TAFINLAR.....	359
TAGRISSE.....	259
TALZENNA	312
TARGRETIN EXTERNAL.....	312
TASIGNA	312
TAVALISSE.....	312
tazarotene external cream	291, 292, 293
TAZORAC EXTERNAL CREAM 0.05 %	291, 292, 293
TAZORAC EXTERNAL GEL 291, 292, 293	TPN ELECTROLYTES INTRAVENOUS CONCENTRATE
TAZVERIK.....	359
TDVAX.....	359
TEFLARO.....	359
TEGSEDI.....	359
TENIVAC	359
TEPMETKO	297
teriparatide (recombinant).....	106, 107
testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml, 200 mg/ml (1 ml) 298, 299, 300, 301, 302, 303	TREXALL
testosterone enanthate intramuscular solution.....	298, 299, 300, 301, 302, 303
testosterone transdermal gel 10 mg/act (2%), 12.5 mg/act (1%), 20.25 mg/1.25gm	trientine hcl
	316, 317
	TRIKAFTA.....
	318
	TROPHAMINE INTRAVENOUS SOLUTION 10 %
	359
	TUKYSA
	319
	TURALIO
	320
	TYMLOS
	321
	V
	VALCHLOR.....
	322
	VARIZIG INTRAMUSCULAR SOLUTION.....
	323, 324
	VARUBI (180 MG DOSE).....
	359
	VEMLIDY
	121, 122, 123
	VENCLEXTA.....
	325, 326
	VENCLEXTA STARTING PACK 325, 326
	VERQUVO
	327
	VERZENIO.....
	328, 329
	vigabatrin
	330
	VIGADRONE.....
	330
	VITRAKVI
	332
	VIZIMPRO
	333

H1587_PA21_C

Formulary ID: 21331 Version 10

Last Updated: 04/30/2021

Effective date: 05/01/2021

Tribute Health Plan 2021 Formulary Prior Authorization Criteria

VOSEVI.....	124, 125	XPOVIO (80 MG ONCE WEEKLY)....	341, 342, 343, 344, 345
VOTRIENT.....	334	XPOVIO (80 MG TWICE WEEKLY)..	341, 342, 343, 344, 345
X		XTANDI	346
XALKORI.....	335	XYREM	347
XATMEP	359	XYWAV	348
XELJANZ.....	336	Y	
XELJANZ XR	336	YONSA.....	349
XGEVA.....	338	Z	
XOLAIR	339	ZARXIO	350
XOSPATA	340	ZEJULA	351
XPOVIO (100 MG ONCE WEEKLY)..	341, 342, 343, 344, 345	ZELBORAF.....	352
XPOVIO (40 MG ONCE WEEKLY)....	341, 342, 343, 344, 345	ZIEXTENZO	353
XPOVIO (40 MG TWICE WEEKLY)..	341, 342, 343, 344, 345	ZOLINZA	354
XPOVIO (60 MG ONCE WEEKLY)....	341, 342, 343, 344, 345	ZORTRESS ORAL TABLET 1 MG.....	359
XPOVIO (60 MG TWICE WEEKLY)..	341, 342, 343, 344, 345	ZYDELIG	355
		ZYKADIA ORAL TABLET	356, 357

H1587_PA21_C

Formulary ID: 21331 Version 10

Last Updated: 04/30/2021

Effective date: 05/01/2021